



Development and evaluation of new approaches for fluorescence-
guided surgery and therapy of pancreatic ductal adenocarcinoma 






In partial fulfilment of the requirements for the degree 
"Doctor rerum naturalium (Dr. rer. nat.)" 
in the Molecular Medicine Study Program 






submitted by Mara Saccomano, M.Sc. 
born in Portogruaro (Venezia, Italy) 
 
Göttingen, May 2016 
  
 




 Prof. Dr. Frauke Alves 
 
Department of Haematology and Medical Oncology, Institute of Diagnostic and 
Interventional Radiology (Georg-August University Medical School of Göttingen) 
and 
Department of Molecular Biology of Neuronal Systems (Max-Planck Institute for 
Experimental Medicine, Göttingen) 
 
Second member of the Thesis Committee 
 
 Prof. Dr. Blanche Schwappach 
 
Department of Molecular Biology (Georg-August University Medical School of 
Göttingen / Max-Planck Institute for Biophysical Chemistry, Göttingen) 
 
Third member of the Thesis Committee  
 
• Prof. Dr. Hubertus Jarry 
 




















Here I declare that my doctoral thesis entitled "Development and evaluation of new 
approaches for fluorescence-guided surgery and therapy of pancreatic ductal 
adenocarcinoma (PDAC) using orthotopic mouse models” has been written 
independently with no other sources and aids than quoted. 
 
Mara Saccomano 

















If you think you can, you can. 
If you think you can’t, you are right. 
 
List of Publications 
I 
List of Publications 
 
Zeeberg K., Cardone R.A., Greco M.R., Saccomano M., Nøhr-Nielsen A., Alves F., 
Pedersen S.F., and Reshkin S.J.: Assessment of different 3D culture systems to study 
tumor phenotype and chemosensitivity in pancreatic ductal adenocarcinoma (PDAC). 
Oncology Report, 2016. (in press) 
 
Saccomano M., Dullin C., Alves F., and Napp J.: Preclinical evaluation of near-infrared 
(NIR) fluorescently labeled Cetuximab as a potential tool for fluorescence-guided surgery. 
International Journal of Cancer, 2016. (submitted, under review) 
 
Giannuzzo A.*, Saccomano M.*, Napp J., Alves F.*, and Novak I.*: Therapeutic targeting 
of the P2X7 receptor in pancreatic cancer and stellate cells. International Journal of 
Cancer, 2016. (submitted, under revision) 
* equal contribution  
 
Cardone R.A., Greco M.R., Zeeberg K., Zaccagnino A., Saccomano M., Bellizzi A., Bruns 
P., Menga M., Pilarsky C., Schwab A., Alves F., Kalthoff H., Casavola V., and Reshkin 
S.J.: NHE1-centered signaling cassette drives Epidermal Growth Factor Receptor–
Dependent Pancreatic Tumor Metastasis and Is a Target for Combination Therapy. 
Neoplasia. 2015 Feb;17(2):155-66. doi: 10.1016/j.neo.2014.12.003. 
 
Table of Content 
II 
Table of Content 
 
List of Publications ....................................................................................................................... I 
Table of Content .......................................................................................................................... II 
Acknowledgements ....................................................................................................................V 
Abstract ....................................................................................................................................... VII 
List of Figures ................................................................................................................................ X 
List of Tables ............................................................................................................................... XI 
List of Abbreviations ...............................................................................................................XII 
1. Introduction .............................................................................................................................. 1 
1.1 Anatomy and physiology of the pancreas .............................................................................. 1 
1.2 Pancreatic Ductal Adenocarcinoma (PDAC) ......................................................................... 1 
1.2.1 Desmoplastic reaction ..............................................................................................................................2 
1.2.2 Treatment ......................................................................................................................................................3 
1.2.2.1 Early stage disease ......................................................................................................................................................3 
1.2.3.2 Locally advanced and systemic PDAC .................................................................................................................4 
1.3. Orthotopic PDAC mouse models .............................................................................................. 4 
1.4. Molecular imaging for tumor monitoring in preclinical models ................................. 5 
1.4.1 Computed tomography ............................................................................................................................6 
1.4.2 In vivo fluorescence imaging ..................................................................................................................6 
1.4.2.1 Fluorescent labels for in vivo NIRF imaging .....................................................................................................6 
1.4.2.2 The principle of in vivo fluorescence imaging .................................................................................................8 
1.5 Fluorescence-guided surgery ..................................................................................................... 9 
1.6 Targeting EGFR and NHE1 in cancer ..................................................................................... 10 
1.6.1 The role of EGFR in cancer................................................................................................................... 10 
1.6.1.1 Cetuximab as antibody-based targeting of EGFR ....................................................................................... 12 
1.6.1.2 Erlotinib as tyrosine kinase inhibitor of EGFR ............................................................................................ 12 
1.6.2 The role of NHE1 in cancer .................................................................................................................. 12 
1.6.2.1 Cariporide ..................................................................................................................................................................... 14 
Aims of the Study ...................................................................................................................... 15 
2 Material and Methods.......................................................................................................... 17 
2.1 Material ........................................................................................................................................... 17 
2.1.1 Equipment .................................................................................................................................................. 17 
2.1.2 Consumable supplies ............................................................................................................................. 18 
2.1.3 Chemicals and reagents ........................................................................................................................ 19 
2.1.4 Buffers and freezing medium ............................................................................................................. 20 
2.1.5 Kits ................................................................................................................................................................. 20 
2.1.6 Anesthetics and Analgesic.................................................................................................................... 21 
2.1.7 Fluorescent probes ................................................................................................................................. 21 
2.1.8 Therapeutic Drugs................................................................................................................................... 21 
2.1.9 Antibodies ................................................................................................................................................... 22 
2.1.10 Eukaryotic cell lines ............................................................................................................................. 22 
2.1.11 Cell culture media ................................................................................................................................. 23 
2.1.12 Software .................................................................................................................................................... 23 
2.1.13 Animals ..................................................................................................................................................... 23 
2.2. Methods.......................................................................................................................................... 24 
2.2.1 Molecular Biology .................................................................................................................................... 24 
Table of Content 
III 
2.2.1.1 Protein extraction and BCA protein assay ..................................................................................................... 24 
2.2.1.2 SDS-PAGE and Western Blot ................................................................................................................................ 24 
2.2.2 Cell biological methods ......................................................................................................................... 25 
2.2.2.1 Cell culture conditions ............................................................................................................................................ 25 
2.2.2.2 Cryoconservation ...................................................................................................................................................... 25 
2.2.2.3 Revitalization .............................................................................................................................................................. 26 
2.2.2.4 In vitro binding assay to PDAC cells for Cetuximab NIRF conjugates ................................................ 26 
2.2.2.5 Cell preparation for implantation ...................................................................................................................... 26 
2.2.3 In vivo experiments ................................................................................................................................. 27 
2.2.3.1 Orthotopic PDAC mouse models ........................................................................................................................ 27 
2.2.3.2 NIRF fluorescence imaging ................................................................................................................................... 28 
2.2.3.3 Co-registration of fluorescence tomography and CT data ...................................................................... 31 
2.2.3.4 Fluorescence-guided dissection ......................................................................................................................... 32 
2.2.3.5 Schedule and evaluation of Cariporide-Erlotinib treatment ................................................................. 33 
2.2.3.6 Tissue preparation ................................................................................................................................................... 34 
2.2.4 Histology of tissue sections ................................................................................................................. 34 
2.2.4.1 Hematoxylin-Eosin (HE) staining ...................................................................................................................... 34 
2.2.4.2 Immunohistochemistry staining of tissue sections ................................................................................... 35 
2.2.4.3 Collagen staining ....................................................................................................................................................... 35 
2.2.5 NIRF analysis of tumor and metastases sections ....................................................................... 36 
2.2.5.1 Immunofluorescence and NIRF microscopy ................................................................................................. 36 
2.2.5.2 Odyssey scans of tissue sections ........................................................................................................................ 37 
2.2.6 Statistical analysis ................................................................................................................................... 37 
3. Results ..................................................................................................................................... 38 
3.1 Orthotopic human PDAC mouse models ............................................................................. 38 
3.1.1 Growth characteristics and time of tumor development ........................................................ 38 
3.1.2 Histological features and desmoplastic reaction of primary tumors developed in 
PDAC mouse models .......................................................................................................................................... 39 
3.2 NIRF labeled Cetuximab targeting EGFR as a tool for fluorescence-guided surgery
 ................................................................................................................................................................... 42 
3.2.1 Characterization of PDAC cell lines for EGFR expression ....................................................... 42 
3.2.2 In vitro binding studies of NIRF labeled Cetuximab to EGFR expressing PDAC cells ..................... 43 
3.2.3 Characterization of EGFR expressing orthotopic PDAC xenografts ................................... 44 
3.2.3.1 Tumor growth, invasion and metastatic spread of ASPC-1 and MIA PaCa-2 mouse models .. 45 
3.2.3.2 Characterization of EGFR expression in tumor tissue obtained from PDAC mouse models ... 46 
3.2.4 Characterization of the in vivo binding of Cetux-Alexa-647 in EGFR expressing PDAC 
xenografts .............................................................................................................................................................. 47 
3.2.4.1 Cetux-Alexa-647 accumulates within primary PDAC tumors in vivo ................................................ 47 
3.2.4.2 Validation of the specificity of in vivo signals by fluorescence LTs .................................................... 51 
3.2.5 Cetux-Alexa-647 detects PDAC primary tumors and metastases by ex vivo optical 
imaging ................................................................................................................................................................... 52 
3.2.6 Validation of Cetux-Alexa-647 fluorescence by NIRF microscopy ...................................... 55 
3.2.7 Cetux-800CW detects AsPC-1 tumors and metastases during fluorescence-guided 
dissection ............................................................................................................................................................... 56 
3.2.8 Ex vivo validation of Cetux-800CW fluorescence signals of tumor and metastases .... 58 
3.3 Proof-of-Concept: Validation of treatment efficacy targeting EGFR in combination 
with NHE1 in the orthotopic AsPC-1 tumor mouse model ................................................... 59 
3.3.1 Treatment schedule of Erlotinib/Cariporide therapy in AsPC1 tumor bearing mice .................... 59 
3.3.2 Tolerance of the treatment and effect on body weight of the mice........................................................ 60 
3.3.3 Effect of Erlotinib/Cariporide therapy on primary tumor growth ......................................................... 61 
3.3.4 Effect of Erlotinib/Cariporide therapy on tumor infiltration into the stomach and duodenum
 .......................................................................................................................................................................................................... 62 
3.3.5 Effect of Erlotinib/Cariporide therapy on metastatic spread ................................................................... 64 
4. Discussion ............................................................................................................................... 67 
4.1 Orthotopic human PDAC mouse models with distinct growth and metastatic 
behavior ................................................................................................................................................. 67 
Table of Content 
IV 
4.2 NIRF labeled Cetuximab as a tool for fluorescence-guided surgery ......................... 70 
4.2.1 Visualization of PDAC primary tumors and metastases with Cetux-Alexa-647 by NIRF 
imaging ................................................................................................................................................................... 70 
4.2.2 Identification of AsPC-1 primary tumor and metastatic sites with Cetux-800CW by 
fluorescence-guided dissection .................................................................................................................... 72 
4.3 Anti metastatic effect of NHE1 and EGFR inhibition in PDAC xenografts ................ 73 
5. Summary and Conclusions ............................................................................................... 76 
Bibliography ............................................................................................................................... 78 








First and foremost, I want to express my deep gratitude to my supervisor Prof. Dr. Frauke 
Alves for the tremendous opportunity that she gave me by choosing me as EU-Marie 
Curie fellow in her lab and being part of the amazing group that turned out to be ‘IonTrac’. 
Moreover, I would like to thank her for giving me the possibility to develop such different 
projects and to collaborate with different research groups. Last, I want to thank her for the 
high quality of critical support for this thesis which will definitely help me on growing as a 
researcher. 
 
I also would like to acknowledge the members of my Thesis Committee, Prof. Dr. Blanche 
Schwappach and Prof. Dr. Hubertus Jarry, together with Prof. Dr. Luis Pardo and Prof. Dr. 
Walter Stühmer, for participating at my PhD thesis committee meetings and for the nice 
and fruitful discussions on my data. 
 
Moreover, I am indebted to Dr. Joanna Napp, who did a great job in motivating and 
directing me towards the last months of this project. 
 
The endeavor of such a study, would have not been certainly possible without the 
practical help of many people for whose support I am very grateful: Roswitha Streich, 
Mercedes Martin-Ortega, Sarah Garbode, Sabine Wolfgramm, Bettina Jeep and Hanna 
Puchala. But among all, the one who really made these results possible, is Bärbel 
Heidrich, who gave me a tremendous help and support during the whole 4 years of my 
project. Not only regarding work but also at personal level. Herzliches Dankeschön, 
Bärbel!  
Together with them, I would also like to thank all the members of the AG Alves, especially 
Dr. Andrea Markus and Dr. Christian Dullin, for the great help during the submission of the 
thesis, and Dr. Fernanda Ramos Gomes, for her constant inspiring happiness. 
 
I would also like to thank Prof. Dr. Reshkin, together with his group from University of Bari, 
for the nice collaboration we planned together, and for being so helpful during the 
thousands of skype calls that I required. He was always available to discuss my research 




This study was financially supported by “IonTrac” EU - project. It was a pleasure to share 
that experience with so many different PhDs around Europe. One especially turned out to 
be not only a great colleague but also an amazing friend: Grazie Andrea!  
Together with Andrea Giannuzzo, I owe thanks to his supervisor, Prof. Dr. Ivana Novak, 
for hosting me during my secondment in Copenhagen and for the nice collaboration that 
we have established. 
 
Then, a big thanks goes to all my friends I have met along the last 4 years here in 
Göttingen. My flatmates, Eva and Marco, the PizzaPasta group, with whom I shared some 
of the best moments ever here in Göttingen, and the MonsterParty Group. Among them, a 
big thanks goes to Giulia Poggi, semplicemente perchè sei come sei! 
 
But moreover and most importantly, I want to thank the 3 most important person I have in 
my live, who have encourage and support me every single day (thanks skype!) during the 
entire course of my PhD: Un grazie infinito ai miei genitori e a mia sorella Giulia, che 
OGNI SINGOLO GIORNO di questo dottorato mi hanno spronato ad andare avanti fino ad 
ottenere un simile risultato. 
Un sincero grazie va anche alle mie zie Luciana e Mara per avermi fatto sempre sentire la 
loro vicinanza e il loro supporto. 
 
And finally, the biggest “thank you” and gratitude goes to my ‘better half’, who has 
supported me along this last 4 years, being constantly at my side and always there in 
case of need, despite we liveD so far from each other. Ti dedico questo traguardo, Paolo. 







Pancreatic cancer has the poorest survival rate of the most common types of cancers with 
a 5 year survival rate of only 3-5% after diagnosis. Since there has been no significant 
improvement in the clinical outcome for several decades, there is an urgent need for novel 
concepts in the understanding of the pathophysiology, diagnosis and treatment of PDAC. 
Therefore, the aim of the study was to characterize the in vivo tumor progression and 
metastatic behavior of PDAC orthotopic mouse models, developing PDAC tumors with 
different grades of differentiation and to assess novel imaging strategies as well as a new 
combination therapy in some of these models. 
To this end, PDAC xenografts were extensively characterized after orthotopic 
transplantation of five different human PDAC cell lines with known grade of differentiation 
(AsPC-1, MIA PaCa-2 and PANC-1 as poorly differentiated, BxPC-3 as moderately 
differentiated and Capan-1 as well differentiated) in the head of the pancreas of nude 
mice. Tumors that developed in each mouse model showed distinct tumor take rates and 
different time of tumor development, independently from the grade of differentiation. All of 
them presented with invasion into the stomach and duodenum, resembling the classic 
features of PDAC progression in humans. The differentiated tumors were composed of 
tumor cells organized in duct-like clusters (Capan-1), as seen in humans, and in round 
clusters (BxPC-3), whereas the poorly differentiated tumors (AsPC-1, MIA PaCa-2 and 
PANC-1) showed a typical unorganized morphology. Moreover, by analyzing the presence 
of PSCs and collagen deposition, in each PDAC mouse model different degrees of a 
desmoplastic reaction, another hallmark of human PDAC, were observed. Similar to 
human PDAC, high amounts of collagen fibers around the duct-like cell clusters were only 
found in Capan-1 tumors. 
Two EGFR expressing PDAC models, AsPC-1 and MIA PaCa-2, were applied for testing 
the suitability of near-infrared fluorescent (NIRF) labeled Cetuximab, a therapeutic 
monoclonal antibody targeting the human epidermal growth factor receptor (EGFR), as a 
new tool for fluorescence-guided surgery (FGS). Distribution and binding of systemically 
injected Cetuximab Alexa Fluor 647 conjugate (Cetux-Alexa-647) and the co-injected 
control human IgG Alexa 750 conjugate (hIgG-Alexa-750) (25 µg each) were studied over 
48 h by NIRF imaging (Optix MX2 and IVIS) in mice bearing orthotopic AsPC-1 and MIA 
PaCa-2 tumors. Results obtained here showed that Cetux-Alexa-647 but not the control 
hIgG-Alexa-750 fluorescence was specifically detected in vivo and ex vivo in the primary 
pancreatic tumors and metastases as small as 1 mm, with maximum intensities at 24 h. 
Abstract 
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LT analysis and NIRF microscopy of tumor sections confirmed the binding specificity of 
Cetux-Alexa-647 to PDAC cells, whereas a multimodal approach applying 3D NIRF 
imaging and CT of AsPC-1 mice receiving both, the Cetux-Alexa-647 and iodine 
containing CT contrast agent, confirmed that the Cetux-Alexa-647 signal localized at the 
primary pancreatic tumor in correlation with the anatomical structure of the mice. 
Moreover, during fluorescence-guided dissection, performed 24 h after injection of the 
probe using the Quest Spectrum clinical device for FGS, Cetuximab conjugated to IRDye-
800CW (Cetux-800CW) enabled fast and straightforward real time delineation of AsPC-1 
tumor margins and also of small metastases. Odyssey scans revealed that only the vital 
part of the tumor, but not the necrotic part, was stained with Cetux-800CW. Tumor cells 
invading into the stomach and duodenum were also detected. Moreover, ex vivo scans of 
organs with detected metastases during fluorescence-guided dissection, also revealed 
high signals only at the metastatic sites and not in the healthy tissue. Taken together, 
NIRF labeled Cetuximab might be a promising tool for the visualization of tumor margins 
and metastatic sites during FGS, allowing a precise surgical resection and consequently 
aiding the decrease of disease recurrence. 
Finally, a combination of Erlotinib, a TKi of EGFR, and Cariporide, a specific inhibitor of 
NHE1, was tested in vivo in the highly metastatic AsPC-1 mouse model to determine their 
effect on tumor growth, invasion and metastatic spread. 10 days after cell transplantation 
AsPC-1 mice were divided in 4 groups and treated for 20 days with Erlotinib (50 mg/kg) or 
Cariporide (3 mg/kg) only or with the combination of both. The control group received 
saline solution and Captisol 6%. Primary tumor and tumor spread in different peritoneal 
organs (liver, spleen, kidney, diaphragm, mesentery and site of surgical incision) were 
analyzed. Quantification of the metastatic spread was difficult to obtain, due to the low 
number of metastatic findings in each organ and to the high variation of the data within 
each treated group. However, Erlotinib/Cariporide-double treated mice presented with less 
metastatic spread to different organs such as liver, kidney and mesentery, and tumor 
infiltration of the site of surgical incision. Moreover, Erlotinib/Cariporide-double therapy 
showed a slight but no significant inhibitory effect on tumor growth as compared to 
controls, and decreased the grade of tumor infiltration in the stomach. Individual therapies 
with either Erlotinib and Cariporide did not show any therapeutic response, neither to 
tumor growth nor to tumor invasion in the stomach, but the metastatic spread to the 
kidney (Erlotinib treated group) and to the diaphragm (Cariporide-treated group) was 
slightly reduced. Taken together, this study provides a preclinical proof-of-concept for a 
novel anti-metastatic activity of Erlotinib/Cariporide-double therapy based on the inhibition 
of both, EGFR, whose overexpression usually correlates with an advanced cancer 
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disease, and NHE1, a protein interconnected with the EGFR downstream signaling and 
implicated in the pH regulation of cell invasion. 
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1.1 Anatomy and physiology of the pancreas 
The pancreas is a combined endocrine and exocrine gland deeply located in the upper-
retroperitoneal cavity. It can be divided into four parts: head, neck, body, and tail. In 
humans, the pancreatic head, located on the right of the superior mesenteric vein, is 
closely associated with the pyloric antrum and the upper part of the duodenum, through 
the pancreatic duct. The pancreatic neck is the constricted portion to the left of the head, 
whereas the body and tail of the pancreas are located on the left side of the abdomen 
behind the stomach in the proximity of the spleen (Figure 1). 
 
 
Figure 1: Anatomical localization of human 
pancreas. The pancreas is located posterior and 
inferior to the stomach on the left side of the 
abdominal cavity. It extends laterally and 
superiorly across the abdomen from the curve of 






Functionally, the pancreas is a complex organ consisting of a combination of different cell 
lineages: an endocrine portion that is arranged as discrete islets of Langerhans, involved 
in the regulation of metabolism and glucose homeostasis, and an exocrine part that 
consists of acinar cells synthesizing and secreting digestive enzymes concentrated into a 
bicarbonate rich fluid that is drained into the small intestine by a complex duct system [2]. 
 
1.2 Pancreatic Ductal Adenocarcinoma (PDAC) 
Each cell type forming pancreas can potentially lead to cancer formation. Depending on 
the cell origin of the tumor, pancreatic cancer can be divided in two main groups: cancers 
that occur in the exocrine part of the pancreas and those that occur in the endocrine one. 
Tumors of exocrine pancreas are far more common accounting for 95% of all cases, 
developing in glands or ducts of the exocrine pancreas, where digestive juices are 
produced. Pancreatic ductal adenocarcinoma (PDAC) typically affects people in their late 
adult life with 80% of PDAC arising between the ages of 60 and 80 whereas it is extremely 
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rare in young people (< 40 years) [3] and more prevalent in males than in females [4]. 
PDAC is the fourth leading cause of cancer death in men and women in western societies, 
with a 5-year survival rate of less than 5% [5]. This extremely poor prognosis is largely 
attributed to its propensity for early local infiltration into surrounding organs including 
stomach and duodenum, to peritoneal metastases into the liver and spleen and distant 
metastases into the lymphatic system and lungs [6-8]. The most common symptoms of 
PDAC include abdominal pain, weight loss, digestive problems and chronic fatigue, 
whereas jaundice is the most common clinical sign. Since the presenting signs and 
symptoms can be caused by multiple other conditions, PDAC is often overlooked during 
differential diagnosis or develops asymptomatically at early stages. Therefore, the 
diagnosis usually occurs in the late onset of the disease, when it has already 
disseminated to surrounding or distant organs and vessels [9]. 
 
1.2.1 Desmoplastic reaction 
Although PDAC shows a highly aggressive behavior, histologically it usually appears well 
differentiated, comprising a well formed tubular or duct-like structure with cuboidal 
epithelium. However, varying degrees of cellular atypia and differentiation are also 
common features [10]. PDAC is one of the most stroma-rich cancers, characterized by a 
remarkable increase in fibrotic tissue that infiltrates and envelopes the neoplasm, referred 
to as the desmoplastic reaction. The resulting fibrosis is composed of a dynamic 
assortment of extracellular matrix (ECM) components, such as collagen type I and other 
glycoproteins, and non-neoplastic cells including fibroblastic, vascular and immune cells, 




Figure 2: Desmoplastic reaction of human PDAC. 
Hematoxylin and eosin stained section of a human PDAC 
showing tumor elements (black arrows) embedded in an 
abundant collagenous stroma (asterisks). Figure taken 




There is now unequivocal evidence that fibrosis of PDAC is mainly produced by 
pancreatic stellate cells (PSCs). PSCs are fibroblast-like cells residing in the exocrinal 
areas of the pancreas in a quiescent status and are activated during the pathogenesis of 
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PDAC. When activated, PSCs assume a myofibroblast phenotype and exhibit expression 
of the cytoskeletal protein α-smooth muscle actin (α-SMA) [13]. Substantial evidence 
indicates that PSCs interact closely with cancer cells to modulate their proliferation and 
migration and play an important role in the chemoresistance of PDAC as well as in the 




1.2.2.1 Early stage disease 
Only 10-15% of the PDAC cases have localized disease (tumor at stage I or II) and can 
therefore undergo a resection procedure. For this, depending on the tumor location and 
type, different surgical resections are considered: pancreatoduodenectomy, or Whipple 
procedure (Figure 3), is preferred for tumors of the head of pancreas, distal pancreatomy 
for tumors located in the tail of the pancreas or a total pancreatectomy for large cystic 
lesions.  
Within patients that underwent resection, the incidence of the so called R1-resection 
(microscopical presence of tumor cells at the resection margins) is quite high and varies 
considerably in the literature ranging from <20% to >80% [14, 15] meaning that 
microscopically positive tumor margins remain after surgical resection resulting in a high 
risk of local tumor recurrence. Therefore, after surgery, PDAC patients usually receive an 
adjuvant chemotherapy to improve the progression-free survival [16], but the overall 
survival is only marginally affected [17].  
 
 
Figure 3: The Whipple procedure. Anatomical view before (a) and after (b) the surgical intervention; note the 
anastomosis of the hepatic duct and the remaining pancreas and stomach to the jejunum (b). Figure taken 




1.2.3.2 Locally advanced and systemic PDAC 
Most of the patients that are diagnosed with PDAC (~80% of the cases) present with a 
locally advanced or metastatic disease (tumors at stage III and IV) and are consequently 
not suitable for surgery. Over the two last decades, the first-line therapy for these patients 
has been the chemotherapeutic agent gemcitabine, a pyrimidine analog, administered as 
monotherapy [18]. However, since numerous patients do not respond to gemcitabine 
therapy due to chemoresistance [19], chemotherapeutic alternatives have been tested 
and only a few have been proven to provide significant prolongation of overall survival 
rates [20]. Among them, FOLFIRINOX (combination of oxaliplatin, irinotecan and 5-FU 
with leucovorin) is now considered as the most promising combination chemotherapy, 
which achieves a significant survival benefit for patients (from 6.8 months with 
gemcitabine alone to 11.1 months with FOLFIRINOX), at the expense though of an 
extremely high toxicity. Therefore, it is suitable only for patients with a good performance 
status [21]. 
In addition to chemotherapies, several studies testing specific therapeutic compounds (i.e. 
monoclonal antibodies or small molecules) in combination with gemcitabine have been 
performed [22]. Among all, only Erlotinib (Tarceva), an inhibitor of the tyrosine kinase (TK) 
activity of epidermal growth factor receptor (EGFR), increased the overall survival of 
PDAC patients from 5.91 to 6.24 months when combined with gemcitabine monotherapy 
and was approved as first-line therapy of PDAC [23]. 
However, neither FOLFIRINOX nor the Erlotinib/Gemcitabine combination improves the 
overall survival by much and therefore, new therapeutic approaches are in high demand 
for PDAC. 
 
1.3. Orthotopic PDAC mouse models 
Mouse PDAC models have been crucial for a better understanding of the molecular 
mechanisms regulating the development of PDAC, as well as its prevention, diagnosis 
and treatment. One of the most widely used animal models in oncology is the human 
tumor xenograft in immunodeficient mice. Orthotopic transplantation of tumor cells in the 
corresponding organ of the mouse, e.g. PDAC cells into the pancreas, results in a tumor 
formation comparable to the one observed in humans in terms of tumor morphology, 
expression of tumor markers, presence of desmoplastic reaction, invasiveness and 
metastatic spread to distant organ such as lymph nodes and lungs [24-26]. 
In order to avoid rejection of the transplanted human cells/tissue by the immune system of 
the host mouse, these models require the use of totally or partially immunodeficient mice 
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such as athymic nude mice that are characterized by a genetic spontaneous mutation of 
the Foxn1nu/nu gene responsible for the maturation of the thymus gland. Therefore, these 
mice are unable to produce mature T cells and consequentially lack cell-mediated 
immunity whereas the innate response remains intact. Moreover, these mice are hairless 
and therefore they are extremely useful and practical for optical imaging studies. 
 
1.4. Molecular imaging for tumor monitoring in preclinical models 
The in vivo evaluation of the suitability of novel diagnostic tumor markers as well as the 
efficacy of novel therapeutic strategies by imaging over time is of growing interest. 
Imaging strategies with CT (computed tomography), MRI (magnetic resonance imaging) 
and US (ultrasound), are mainly employed to detect anatomical structures of the body 
including internal organs. Nuclear imaging including SPECT (single photon emission 
computed tomography) and PET (positron emission tomography), and optical imaging 
including fluorescence and bioluminescence imaging, are considered as functional 
imaging, since they are able to assess molecular processes such as physiological or 
metabolic activities in vivo [27]. The choice of a particular imaging technology for a 
particular research depends on different factors required for the study such as imaging 
frequency, field of application and required spatial resolution. Since each imaging 
technique has unique advantages and limitations (Table 1), in general they are more 
complementary than competitive, and researchers increasingly combine them [28]. 
 
 
Table 1: Overview of characteristic features of different in vivo small-animal imaging modalities. Each 
modality is characterized by specific detection modality, resolution, penetration depth, agents employed, field 
of study and cost. Most imaging modalities are used clinically and can be translated from animals to humans 




1.4.1 Computed tomography 
To date, CT is the workhorse of anatomical imaging not only in clinical but also in 
preclinical oncology since it is fast, cost-effective, non-invasive and obtains high resolution 
images. It consists of an X-ray source and X-ray detectors between which the subject is 
placed. Most systems commonly use cone-beam X-ray source and solid-state detectors 
that rotate around the animal to produce projections of X-ray attenuation through the body 
at many different angles [29]. Then, CT makes use of computer-processed combinations 
of the multiple X-ray images taken to produce cross sectional images of the scanned area. 
Digital geometry processing of the radiographic images can further be used to generate a 
three dimensional (3D) view of the region of interest (ROI) [30]. To assess tumor growth 
by CT, the use of iodine containing contrast agents is necessary as tumors without 
contrast agents can generally not be distinguished from their surrounding soft tissues. 
 
1.4.2 In vivo fluorescence imaging 
In vivo fluorescence imaging of small animals is unequivocally the most versatile 
visualization modality, which is increasingly employed across the drug development 
process, particularly in the oncology/cancer therapeutic area. One of the main applications 
is monitoring the treatment response for early indications of efficacy. 
 
1.4.2.1 Fluorescent labels for in vivo NIRF imaging 
Fluorescence is the property of certain molecules to absorb light at one wavelength and to 
emit light at a longer wavelength [31]. It takes place when an orbital electron of the 
molecule interacting with a photon, absorbs its energy and thereby is excited to a higher 
quantum state. Since this state is unstable, the electron relaxes back to its ground state 
by emitting fluorescence light [32]. Today, fluorophores in many colors exist that fluoresce 
from deep blue (~400 nm) in the visible spectrum to far red (~900 nm). Of particular 
advantage for optical imaging in animals are fluorophores absorbing and emitting in the 
near- infrared (NIR) wavelength region of 700 to 900 nm. The advantage of this spectral 
range is not only a decreased autofluorescence, when compared to the blue range (400-
500 nm), but also less absorbance occurs by components of the blood such as 
haemoglobin and water (Figure 4). For this reason, NIRF imaging enables the best 
penetration of light into the tissue, and fluorophores that absorb in this window are 




Figure 4: Tissue optical window. The absorption (illustrated as absorption coefficient) by major light 
absorbers in tissue is illustrated at distinct wavelengths. In the optical window (700 to 900 nm; light blue) 
absorption by hemoglobin (Hb), oxygenated hemoglobin (HbO2), and water (H2O) is low. Figure taken from 
Phan et al. [34]. 
 
Fluorescent probes for in vivo imaging can be divided in three groups, i) non-targeted or 
unspecific contrast agents, ii) targeted labels, depending on their association to a specific 
ligand directed against disease relevant molecules, and iii) activatable probes. 
Non-targeted tracers are characterized by a sufficiently long blood circulation time and are 
mainly designed for imaging of blood vessels or blood vessel leakiness. Three unspecific 
NIR fluorophores available in the clinic are: indocyanine green (ICG), methylene blue 
(MB) and 5-aminolevulinic acid (5-ALA). The clinically most used NIRF dye is ICG, a 
tricarbocyanine dye, which is FDA approved since 2006 for cerebral and retinal 
angiography and for liver clearance in humans. Furthermore, ICG has been shown to be a 
valid alternative to radiotracers in sentinel lymph node mapping in different types of 
cancers [35]. The enhanced permeability and retention (EPR) effect that involves 
hyperpermeable and leaky vasculature in tumors, as well as suppression of lymphatic 
function allows unspecific probes to extravasate passively, accumulate in the tumor tissue 
and therefore be suitable for tumor studies (i.e. fluorescence-guided surgery (FGS). 
In order to improve the accumulation of fluorescent contrast agents in a specific area of 
interest, NIR- fluorochromes are often conjugated to ligands, such as antibodies, antibody 
fragments (nanobodies or single chain antibodies), or small peptides, which interact with a 
specific molecular target. The probes that bind are retained at the target site (i.e. tumor), 




1.4.2.2 The principle of in vivo fluorescence imaging 
In vivo fluorescence imaging is mostly based on the detection of the fluorescence 
emission from fluorophores, after excitation at a distinct wavelength, in small living 
animals. Different devices for NIRF imaging are currently available on the market. Most of 
them are equipped with a multispectral light source or a laser for excitation of the 
fluorescent probe, appropriate filters to set the desired excitation light as well as to collect 
the fluorescence emission light, and a detector, which is usually either a coupled charge 
device (CCD) camera or a photomultiplier tube. The most common method to record 
fluorescence deeper from the tissues is associated with planar measurements, which are 
usually overlaid with photographic images of the surface of the scanned sample. Planar 
imaging can be performed either in an epi-illumination mode, also called fluorescence 
reflectance imaging (FRI), as well as in transillumination mode, based on the reciprocal 
position of the excitation source and the detector used in relation to the scanned object. 
These are located on the same side of the object in the case of the epi-illumination mode, 
whereas when the excitation source and the detector are placed on the opposite sides of 
the scanned animal, imaging is performed in a trans-illumination mode, in which the light 
penetrating the object is collected [36]. One of the most recent progressions in NIRF 
imaging was the development of tomographic fluorescence imaging, including 
fluorescence molecular tomography (FMT), which requires reconstruction with 
sophisticated image processing algorithms, providing 3D images of the fluorescence 
biodistribution in the whole animal as well as the precise information about the probe 
concentration and depth [37]. 
Although NIRF imaging has a limited tissue penetration depth of ~1 cm, it offers several 
advantages in comparison to other functional imaging technologies, like SPECT or PET. It 
has a high spatial resolution, producing fast and real time measurements with relatively 
low cost. Moreover, it is a highly sensitive technique enabling the detection of fluorophore 
of picomolar or even femtomolar concentrations [38]. Unlike SPECT or PET, a unique 
characteristic of fluorescence imaging is the spectral unmixing analysis, which is able to 
distinguish between several applied fluorescence labels injected simultaneously and 
differing in their emission excitation. Time-domain NIRF imaging is also a well establish 
method for studying the emission dynamics of the fluorescent molecules. This approach 
employs pulsed laser diode as an excitation source, and is able to measure time-resolved 
the emitted photons from the object after each single excitation pulse using a 
photomultiplier tube. Thus, the lifetime (LT), characterizing specifically each fluorescent 
probe by describing the average time it spends in the excited state before returning to the 
ground state, can be calculated over a specific area of the scan. This permits the 
identification of probe-derived signals in vivo [39]. 
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1.5 Fluorescence-guided surgery 
Along with the application in small animal research, NIRF imaging is obtaining more and 
more interest in clinic translation. Due to the low tissue penetration of fluorescent light, 
one of its most promising use in the clinic is image-guided open surgery or laparoscopy, 
e.g. for real time fluorescence guidance for tumor resection in order to minimize the R1 
positive tumor margins [40]. In fact, the high sensitivity of NIR fluorescence imaging 
potentially allows the visualization of a very low number of tumor cells on the surface of a 
tissue (i.e. margin positivity), otherwise only detected by histopathological analysis. 
Different intraoperative imaging systems (SPY, Artemis and FLARE) for open surgery 
(Figure 5a) or laparoscopy (Figure 5b) are available in the clinic [40]. Using these 
systems, NIRF contrast agents can be visualized with acquisition times in the millisecond 
range (Figure 5c) enabling real-time guidance during surgery. The NIR light used for 
monitoring the fluorescence probes is invisible to the human eye, thus not altering the look 
of the surgical field [41]. Moreover, since it does not require the handling of ionizing 
radiation, it can be considered as a relative safe technique. While no standardized 
protocol for fluorescence guidance exists as yet in the routine applied for oncologic 
surgery, clinical trials have been lately conducted in patients using ICG, 5-ALA and MB for 
guidance during the resection of liver metastases, glioma and a fibrous tumor of the 
pancreas, respectively [42-44], providing, in some cases, a modest and useful contrast to 
distinguish the tumor lesions from normal tissue. However, all these probes lack sufficient 
reliability regarding specificity and histopathologic accuracy to establish a consistent real-
time assistance during surgery. In some cases, where fluorescence was reported, the 
difference between tumor and background fluorescence was hardly detectable [45]. 
Therefore, there is a high demand for novel specific fluorescence targeting approaches in 




Figure 5: The approach for fluorescence-guided surgery. Different NIR fluorescence imaging systems are 
available for open surgery (a) or for minimally-invasive laparoscopy (b). (c) For FGS, a NIR fluorescent 
contrast agent is administered intravenously, topically, or intraparenchymally before surgery. During surgery, 
the agent is visualized using adequate NIR excitation light, collection optics and filtration, and a camera 
sensitive to NIR fluorescence emission light. Figures adapted from Vahrmeijer et al. [35] and Quest web site 
(http://www.quest-mi.com). 
 
1.6 Targeting EGFR and NHE1 in cancer 
Today, one of the most promising approaches to detect or treat tumors involves strategies 
targeting tumor associated antigens over-expressed on tumor cells. These antigens are 
usually easily accessible targets, located preferentially on the cell membrane, such as 
mucins, growth factor receptors (i.e. EGFR), ion-channels, or cell-adhesion molecules (i.e. 
integrin receptors) [27, 46, 47]. 
 
1.6.1 The role of EGFR in cancer 
A well-known biomarker of various cancer types is the human EGFR, also called ErbB1 or 
HER1. It is overexpressed in up to 90% of pancreatic cancers [48] and in many other 
human cancers including head and neck squamous-cell carcinoma (HNSCC), colorectal 
and brain cancer [49]. 
EGFR is a transmembrane 170 kDa glycoprotein belonging to the four-member ErbB1-4 
family of tyrosine kinase growth factor receptors. All of them share the same structure 
composed of an extracellular domain, a hydrophobic transmembrane region and a 
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tyrosine kinase-containing cytoplasmic region. Binding of EGF or transforming growth 
factor alpha (TGFα), which are the most important endogenous ligands for EGFR, to its 
extracellular region, promotes major domain reorganization and conformational changes, 
that permit it to dimerize with other receptors of the family [50]. Dimerization results in 
receptor autophosphorylation and further activation of the downstream signaling 
cascades, including Ras-ERK, phosphoinositide-3 kinase and STAT, which are all 
associated with cell growth, proliferation, survival, cell motility, and angiogenesis [51]. Due 
to the increasing knowledge of the structure and function of EGFR and of its role in the 
initiation and progression of various cancers, many efforts have been made in the 
development of new anticancer therapies targeting EGFR. 
Selective compounds have been developed targeting either the extracellular ligand-
binding region of the EGFR using e.g. monoclonal antibodies, immunotoxins and ligand-
binding cytotoxic agents, or the intracellular tyrosine kinase region through the 
employment of small molecules tyrosine kinase inhibitors (TKIs) [52]. Among them are 
monoclonal antibodies, such as Cetuximab or Panitumumab, and TKIs, such as Erlotinib, 
Gefitinib (Figure 6), both currently applied in the clinic. 
 
Figure 6: Inhibition of EGFR. Therapeutic antibodies and tyrosine kinase inhibitors (blue boxes) are directed 
against the ligand-binding cleft in the extracellular domain and to the intracellular kinase domain, respectively. 




1.6.1.1 Cetuximab as antibody-based targeting of EGFR 
Cetuximab (Erbitux) is a chimeric human/mouse monoclonal antibody (150 kDa) that 
specifically binds to the extracellular domain of human EGFR, competing with the natural 
ligands (EGF and TGFα). It has a similar or even higher affinity for the EGFR than the 
natural ligands, and effectively blocks the ligand-induced signaling cascade [54]. There is 
evidence suggesting that, after binding to EFGR, Cetuximab promotes its internalization 
by endocytosis and its further lysosomal degradation, leading to an overall downregulation 
of the number of EGFRs expressed on the surface of the cells [53]. Cetuximab is currently 
approved as a single agent or in combination with radiation therapy for the treatment of 
HNSCC, and as a single agent or in combination with chemotherapy for the treatment of 
colorectal carcinoma [55]. 
 
1.6.1.2 Erlotinib as tyrosine kinase inhibitor of EGFR 
Erlotinib (Tarceva) is a low-molecular weight reversible EGFR TKI. However, it has been 
recently demonstrated that it targets several kinases and should therefore be considered 
as a multikinase inhibitor [56]. Due to its much smaller size in comparison to i.e. 
monoclonal antibodies such as Cetuximab, Erlotinib can act at the cytoplasmatic level, 
where it competes with ATP for binding to the catalytic domain of the tyrosine kinase, 
disrupting the downstream signal transduction of EGFR. Erlotinib has been currently used 
in patients for the treatment of non-small cell lung cancer (NSCLC) and lately it was the 
first EGFR-targeted therapy approved by the US Food and Drug Administration (FDA) for 
the treatment of pancreatic carcinoma, in combination with gemcitabine, although 
presenting only modest survival benefits [23]. 
 
1.6.2 The role of NHE1 in cancer 
Among many factors involved in the maintenance of homeostatic growth of a cell, the tight 
regulation of cellular pH has been considered of high importance. While normal cells 
maintain their intracellular pH (pHi) within a physiological range, malignant cells show an 
acidic extracellular pH (pHe) and an alkaline intracellular pHi [57]. This pH gradient 
creates a perfect environment for metastatic progression, by stimulating acid-activated 
proteases which then facilitate tumor cell invasion and dissemination [58]. The 
development and maintenance of this pathological pH gradient is directly due to an 
overexpression and/or overstimulation of different membrane bound proton transporters 
implicated in the secretion of protons (H+), including the Na+/H+ exchanger NHE1 [59-61], 
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H+ pump ATPase [62, 63] and the monocarboxylate H+ efflux cotransporters MCT1 and 
MCT4 [64-66]. 
Among them, the most extensively studied is the NHE1, one of the 9 isoforms of the 
sodium–hydrogen antiporter family, composed of 12 transmembrane segments at the N 
terminus, mediating a 1:1 exchange of extracellular sodium for intracellular protons across 
the cell membrane [67, 68], and a long C-terminal cytoplasmic tail, that regulates the 
interaction with different cytoskeletal proteins such as the actin binding protein ezrin [68]. 
NHE1 is found in virtually all mammalian tissues and cells where it is involved in the 
regulation of pHi homeostasis, cellular volume and cytoskeletal organization [57]. 
Regulation of NHE1 activity is mediated by multiple extracellular stimuli comprised of 
three major categories: i) ligand receptors of the ECM, such as integrin [69] and CD44 
[70]; ii) physical stimuli such as osmotic cell shrinkage and shear stress (for reviews, see 
[71, 72]); and iii) soluble growth factors, hormones or cytokines acting through receptor 
tyrosine kinases and G-protein coupled receptors, which increase NHE1 activity through 
the classical Ras-mediated ERK cascade [68]. Recently it has been shown that NHE1 is 
an important effector of EGFR driven tumor progression [73]. In addition, there is ample 
evidence that NHE1 can be activated by the components of the tumor metabolic 
microenvironment such as low serum [74, 75], acidic pHe [76] and hypoxia [77-79] (Figure 
7a). 
Recent work has demonstrated that NHE1 is localized at the migratory leading edge of the 
tumor cell membrane, called invadopodia, (Figure 7b) and its activity has a double 
function in driving invadopodia formation and proteolytic activity through the alkalinization 
of the invadopodia cytosol which stimulates the dynamic process of invadopodia 
protrusion [80, 81] and the acidification of the extracellular peri-invadopodia nanospace 
which is necessary for the pHe dependent up-regulation of proteolytic enzymes, above all 
matrix metalloproteinases (MMPs) and cathepsins, implicated in the ECM digestion at the 
front of migrating tumor cells [82, 83]. It has also been observed that the deregulation of 
NHE1 activity is an important factor leading to metastasis in human breast cancer [74]. 
Due to its critical role in tumor progression, different inhibitors of NHE1 have been 





Figure 7: Activation of NHE1 and its role in invadopodia formation. (a) A general scheme showing the 
major systems regulating the activity of NHE1 with the resultant alkalinization of pHi and acidification of pHe. 
These altered intra- and extra-cellular environments drive a series of tumor cell behaviors resulting in 
progression to more aggressive tumor characteristics. (b) The insert is a magnification of the cellular extrusion 
into the ECM called invadopodia. They are F-actin enriched cellular protrusions responsible for ECM 
degradation whose formation is activated by integrin binding to the ECM and where enzymes such as MMP-2 
and MMP-9 are released extracellularly in the peri-invadopodia region. In parallel, NHE1 is responsible for the 
localized production of protons and consequent acidification of this sub-cellular region, resulting in a favorable 
environment for the activation of those enzymes. Figure taken from Reshkin et al. [57] 
 
1.6.2.1 Cariporide 
Cariporide (N-(Aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide) is a 
potent selective inhibitor of NHE1, binding to Na+-binding site of the antiport [84], and 
used in the first instance in different clinical trials for ischemic-reperfusion injury, obtaining 
positive results as a cardioprotective drug, although with a slight cerebrovascular toxicity 
[84]. 
Most recently, the inhibition of NHE1 by Cariporide has also been explored in the 
oncological contest. It has been demonstrated that in vitro Cariporide reduces proliferation 
and induces apoptosis in cholangiocarcinoma cells [85], and inhibits hypoxia-mediated 
tumor invasion and migration of human tongue squamous carcinoma cells [86]. Following 
this approach, the role of the NHE1 in transducing the EGFR signal into increased growth 
and invasion behavior of tumor cells was demonstrated in different PDAC cells. Applying 
Cariporide in combination with the EGFR inhibitor Erlotinib demonstrated already a 
synergistic block of 3D multicellular tumor spheroid growth and of the invadopodia 
proteolitic activity [73]. However, how these very promising in vitro results on the 
synergistic inhibition of 3D growth and invasion by the Cariporide/Erlotinib combination 
can be translated to in vivo to reduce tumor growth and metastatic spread has still to be 
shown. 
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Aims of the Study 
The main objective of my PhD project is to characterize and apply different orthotopic 
human PDAC mouse models to preclinically evaluate novel approaches for the 
visualization and therapy of PDAC. 
The following tasks will be addressed: 
1.  The establishment of orthotopic human PDAC mouse models to provide a broad 
range of different PDAC xenografts (from well to poorly differentiated), resembling 
human pancreatic tumors and their metastatic spread as close as possible, for their 
use in preclinical imaging and therapeutic studies targeting tumor growth, invasion and 
metastatic spread. This will be achieved by: 
 Transplantation of five human PDAC cell lines with diverse differentiation status 
into the head of the pancreas of nude mice. 
 Evaluation of tumor growth rates and time of development of clinically relevant 
symptoms in the different PDAC mouse models. 
 Characterization of tumor morphology, differentiation grade and stroma 
organization. 
 
2.  The evaluation of Cetuximab-NIRF dye conjugates targeting EGFR (Cetux-Alexa-647 
and Cetux-800CW) as new tools for fluorescence-guided surgery (FGS) to detect 
PDAC primary tumor and metastases. This will be achieved by: 
 Assessment of EGFR expression on PDAC cells and tumor tissues within the 
established orthotopic tumor models in order to identify the best suitable model. 
 Analysis of the in vitro binding of Cetux-Alexa-647 and Cetux-800CW conjugates 
to the selected EGFR expressing PDAC cells. 
 Preclinical in vivo and ex vivo evaluation of the tumor targeting specificity of Cetux-
Alexa-647 in comparison to a control hIgG-Alexa-750 conjugate. 
 Visualization of primary tumors and metastases using Cetux-800CW during 
fluorescence-guided dissection. 
 Validation of the binding of Cetuximab-NIRF dye conjugates to tumor tissue by 
NIRF microscopy and Odyssey scans. 
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3.  The efficacy of a combined therapy targeting EGFR and NHE1 on growth, invasion and 
metastatic spread in the highly aggressive AsPC-1 mouse model. This will be achieved 
by: 
 Evaluation of the inhibitory effect of Erlotinib and Cariporide on the primary tumor 
growth, infiltration in the stomach and duodenum and metastatic spread in different 
peritoneal organs. 
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Anesthesia system VisualSonics, Toronto, Ontario, Canada 
Analytical balance Sartorius, Göttingen, Germany 
AxioCamHR camera Carl Zeiss, Göttingen, Germany 
Centrifuge 5810 and 5424 Eppendorf, Hamburg, Germany 
Chemi-Doc XRS luminescence detection 
system 
Bio-Rad, München, Germany 
Cooling centrifuge 5403  Eppendorf, Hamburg, Germany 
Electrophoresis system Xcell SureLockTM Mini-
Cell 
LifeTechnologies (Invitrogen), Darmstadt, 
Germany 
FGS system Quest Spectrum Quest Medical Imaging, Middenmeer, the 
Netherlands 
Fluorescence-Light microscope, Axiovert 200M Carl Zeiss, Göttingen, Germany 
Heating plate Medax, Neumuenster, Germany 
In vivo small animal microCT QuantumFX Perkin Elmer, Waltham, MA, USA 
Incubator, Heraeus BB6220 Heraeus Instruments, Hanau, Germany 
Insulated box (cell freezing) Nalgene Mr. 
Frosty 
Sigma Aldrich, Schnelldorf, Germany 
Laboratory balance Sartorius, Göttingen, Germany 
Laboratory pipettes Eppendorf, Hamburg, Germany 
Light microscope, Telaval 31 Carl Zeiss, Göttingen Germany 
Microtome HM 340E Thermo Scientific, Darmstadt, Germany 
Mini Trans-Blot ® Cells Bio-Rad, München, Germany 
Neubauer counting chamber Schütt Labortechnik, Göttingen, Germany 
Odyssey infrared imaging system Li-Cor Biosciences, Bad Homburg, Germany 
Optical imaging scanner IVIS Spectrum Perkin Elmer, Waltham, MA, USA 
Optical imaging scanner Optix MX2 ART, Montreal, Canada 
ORCA-ER NIR-sensitive camera Hamamatsu, Herrsching am Ammersee, 
Germany  
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pH meter Inolab  WTW, Weiheim, Germany 
Steamer, MultiGourmet Braun, Kronberg, Germany 
Thermomixer Compact 5350 Eppendorf, Hamburg, Germany 
Tissue processor, TP 1020 Leica, Wetzlar, Germany 
Wallac Victor 2 multilabel counter 1420 Perkin Elmer, Waltham, MA, USA 
 
2.1.2 Consumable supplies 
Consumables: Manufacturer: 
Cell culture flasks Sarstedt, Nümbrecht, Germany 
Cellstar 12 wells culture plates Greiner Bio-One, Frickenhausen, Germany 
Cellstar 96 wells culture plates (F-bottom) Greiner Bio-One, Frickenhausen, Germany 
Cover glasses 12 mm Ø Thermo Scientific, Darmstadt, Germany 
Cryotube vials Nunc, Roskilde, Denmark 
Eppendorf tubes Eppendorf, Hamburg, Germany 
Falcontubes 15 ml, 50 ml Corning, New York, USA 
Filter pipette tips, 10 μl, 100 μl, 1000 μl Sarstedt, Nümbrecht, Germany 
Insulin syringes with integrated needle         
(30 G, 0.3 ml) 
BD Bioscience, Heidelberg, Germany 
 
Insulin syringes with integrated needle       
(30G x ½, 0.5 ml) 
B. Braun, Melsungen, Germany 
 
Microscope slides “Superfrost Plus” Thermo Scientific, Darmstadt, Germany 
ibidi µdishes 35 mm/low Ibidi, Martinsried, Germany 
Needles, Sterican, 27G x ¾  BD Bioscience, Heidelberg, Germany 
Nitrocellulose hybridization transfer 
membranes 
GE Healthcare (Amersham), Freiburg, 
Germany 
NuPAGE Novex 3-8 % TRIS-acetate gels Life Technologies, Darmstadt, Germany 
Reusable Oral Gavage Needles Fine Science Tool, Heidelberg, Germany 
Serological pipettes 2 ml, 5 ml, 10 ml Greiner Bio-One, Frickenhausen, Germany 
Serological pipettes 25 ml Corning, New York, USA 
Surgical suture, absorbable, Vicryl 4/0 Johnson & Johnson, Neuss, Germany 
Syringes 1 ml BD Plastipak, Heidelberg, Germany 
Tissue Tek cassette Vogel, Giessen, Germany 
Whatman filter paper Bio-Rad, München, Germany 
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2.1.3 Chemicals and reagents 
Chemicals and reagents: Manufacturer: 
Antibody diluent Dako, Hamburg, Germany 
Antigen-retrieval solution (pH 6) Dako, Hamburg, Germany 
Aqueous mounting medium (Aquatex) Merck, Darmstadt, Germany 
Bovine serum albumine (BSA) Sigma Aldrich, Schnelldorf, Germany 
ColorPlus™ Prestained Protein Ladder #7712 New England BioLabs, Frankfurt am Main, 
Germany 
Western Blot Chemiluminescent HRP 
substrate 
Millipore, Billerica, MA, USA 
DAPI Nucleic Acid Stain  Invitrogen, Darmstadt, Germany 
Diethylpyrocarbonate (DEPC) Water Merck, Darmstadt, Germany 
Dimethylsulfoxide (DMSO) Sigma Aldrich, Schnelldorf, Germany 
DPBS (1x) without Ca2+ and Mg2+ Gibco/Invitrogen, Karlsruhe, Germany 
Eosin G Merck, Darmstadt, Germany 
Ethanol absolute Merck, Darmstadt, Germany 
Fetal bovine serum (FBS) Gold PAA Laboratories, Pasching, Austria 
Formaldehyde 37% Merck, Darmstadt, Germany 
Glycine Apllichem, Darmstadt, Germany 
Haematoxylin (Mayer’s) Merck, Darmstadt, Germany 
Horse serum Gibco/Invitrogen, Karlsruhe, Germany 
Hydrochloric acid, 37% Merck, Darmstadt, Germany 
Hydrogen peroxid (H2O2) 30% Merck, Darmstadt, Germany 
Hydrophobic mounting medium (DePex) Merck, Darmstadt, Germany 
Imeron 300 Bracco, Konstanz, Germany 
Low fluorescent food (Regime 210, 
U8959A01R) 
Scientific Animal Food and Engineering, Augy, 
France 
NuPAGE Antioxidant Invitrogen, Darmstadt, Germany 
NuPAGE Sample Reducing Agent (SRA) 10X Invitrogen, Darmstadt, Germany 
Paraffin (TM 60 °C) Süsse, Guxhagen, Germany 
Paraformaldehyd (pure) Serva, Heidelberg, Germany 
PBS tablets Gibco/Invitrogen, Karlsruhe, Germany 
ProLong gold antifade reagent with DAPI Thermo Scientific, Darmstadt, Germany 
Propanol Chemsolute/Th. Geyer, Höxter, Germany 
RIPA buffer Thermo Scientific, Darmstadt, Germany 
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SEA BLOCK Blocking Buffer Thermo Scientific, Darmstadt, Germany 
Sodium chloride, isotone, 0.9% Braun, Melsungen, Germany 
Target retrieval solution Dako, Hamburg, Germany 
TRIS-HCl Roth, Karlsruhe, Germany 
TRIS-acetate SDS running buffer Invitrogen, Darmstadt, Germany  
Trypsin-EDTA (0.25%) PAA Laboratories, Pasching, Austria  
Tween-20 Sigma-Aldrich, Seelze, Germany 
Western blot stripping buffer Thermo Scientific, Bonn, Germany 
Xylol Merck, Darmstadt, Germany 
 
2.1.4 Buffers and freezing medium  
Buffer: Composition: 
TBS (10x)  1.4 M NaCl, 500 mM Tris-HCl, pH 7.5  
TBST 
1.4 M NaCl, 500 mM Tris-HCl, 0.05% Tween-
20 pH 7.5  
TRIS-glycine 
50 mM TRIS-HCl (pH 7.6), 150 mM NaCl, 0.1 
M glycine (pH 7.4)  




AEC peroxidase substrate kit BD Bioscience, Heidelberg, Germany 
BCA protein assay kit Thermo Scientific, Bonn, Germany 
ECL kit Merck Millipore, Darmstadt, Germany 
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2.1.6 Anesthetics and Analgesic 
Anesthetic: Manufacturer: 
Isoflurane Abbvie, Ludwigshafen, Gemany 
Ketamine 10% Medistar, Ascheberg, Germany 
Xylariem (Xylazine) Ecuphar, Greifswald, Germany 
 
Analgesic: Manufacturer: 
Novaminsulfon (Metamizole) Zentiva, Berlin, Germany 
Rimadyl (Carprofen) Norbrook, Leverkusen, Germany  
 
2.1.7 Fluorescent probes 






EGFR antibody  
Merck,  
Darmstadt, Germany 
Alexa Fluor 647 
Invitrogen, Darmstadt, Germany 
Cetux-Alexa-647 6.7 
IRDye 800CW 
Li-cor Biosciences,                
Bad Homburg vor der Höhe, 
Germany 
Cetux-800CW 0.6 
human IgG1 isotype 
#009-000-003  
Jackson Immunolabs,  
Hamburg, Germany 
Alexa Fluor 750 
Invitrogen, Darmstadt, Germany 
hIgG-Alexa-750 5.3 
 
Couplings and purifications (gel chromatography followed by a preparative gel filtration) of 
the conjugates was performed by Squarix Biotechnology GmbH, Marl, Germany 
 
2.1.8 Therapeutic Drugs 
Substance: Provider: 
Erlotinib HCl (OSI-744) Genentech, South San Francisco, USA 
Cariporide (HOE642) Sanofi-Aventis, Paris, France 
Captisol  Ligand Pharmaceuticals, San Diego, USA 
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2.1.9 Antibodies 
Antibodies: Application: Provider: 
mouse anti-actin mAb, 
#MAB1501 (cl. C4) 
Western Blot 
Merck Millipore, Darmstadt, 
Germany 
goat anti-mouse mAb - HRP Western Blot 
GE Healthcare (Amersham), 
Freiburg, Germany 
goat anti-rabbit mAb - HRP Western Blot 
GE Healthcare (Amersham), 
Freiburg, Germany 
rabbit anti-human EGFR mAb, 
#MA5- 16359, cl. SP9 
Immunohistochemistry 
Thermo Scientific, Darmstadt, 
Germany 
rabbit anti-human α-SMA IgG, 
#ab5694 
Immunohistochemistry Abcam, Cambridge, UK 
Histofine Simple Stain Max PO-R 
(anti-rabbit-HRP) 
Immunohistochemistry 
Nichirei Biosciences, Tsukiji, 
Japan 
goat anti-rabbit IgG, Alexa Fluor 
488 labeled 
Immunofluorecence MoBiTec, Göttingen, Germany 
  
2.1.10 Eukaryotic cell lines 
 
All cells were bought from American type culture collection (ATCC)/LGC, Wesel 
 




nude mouse xenografts initiated with cells from the 
ascites of a 62-year-old woman with 
adenocarcinoma of the head of the pancreas and 




65-year-old man with adenocarcinoma involving the 





56-year-old male with an adenocarcinoma in the 





liver metastasis of a 40-year-old male with a 
pancreas adenocarcinoma in the head of the 




61-year-old woman with adenocarcinoma of the 
pancreas body with no evidences of metastases 
MCF7 human breast cancer  
metastatic pleural effusion of an adenocarcinoma of 
the mammary gland 
MDA MB 468 human breast cancer  
pleural effusion of a 51-year-old black female 
patient with metastatic adenocarcinoma of the 
breast 
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2.1.11 Cell culture media 
Medium: Manufacter: 
DMEM + D-glucose (4.5 g/l), L-glutamine, 
Pyruvate  
Gibco/Invitrogen, Karlsruhe, Germany 
DMEM ⁄ F-12 (1:1) + Glutamax Gibco/Invitrogen, Karlsruhe, Germany 
IMDM + 25 mM HEPES Gibco/Invitrogen, Karlsruhe, Germany 
RPMI 1640 Gibco/Invitrogen, Karlsruhe, Germany 
 
2.1.12 Software 
Program: Used for: 
Artemis Capture Suite, v. 1.1.2 Quest Spectrum (Data acquisition) 
AxioVision Rel., v. 4.6 Axiovert 200M fluorescence microscope  
Image J [85] Image processing  
Image Studio, v. 3.1 Odyssey infrared imaging system 
Living Image, v. 4.4 IVIS Spectrum (Data acquisition and analysis) 
Optix, v 2.02.01 Optix MX2 (Data acquisition) 
OptiView, v 2.01.00 Optix MX2 (Data analysis) 
Past 3.11 [86] Statistical analysis 
Quantity One, v. 4.6.2 Chemi-doc luminescence detection system 
Wallac 1420 Manager, Version 2.0 Victor 2 multilabel counter 
 
2.1.13 Animals 
Male athymic nude mice, strain CD1-Fox1nu/nu were directly purchased from Charles River 
(Sulzfeld, Germany) and used after 2 weeks of adaptation and strain NMRI-Fox1nu/nu were 
initially obtained from Charles River and bred in the Central Animal Facility, University 
Medical Center Göttingen.  




2.2.1 Molecular Biology 
 
2.2.1.1 Protein extraction and BCA protein assay 
 
 Protein extraction 
To obtain cell lysates, cells were detached from the dish as described in section 2.2.2.1, 
transferred to a 15 ml falcon tube, washed twice with Phosphate buffered saline (PBS), 
and resuspended in 100-300 μl of radioimmunoprecipitation assay (RIPA) buffer. After 30 
min of incubation at room temperature (RT), cell debris were centrifuged for 15 min at 
14000 rpm at 4°C and the supernatant was used as total cell extract. 
 
 BCA protein assay 
Protein concentration was determined using the bicinchoninic acid (BCA) protein assay kit 
that employs bovine serum-albumin (BSA) as a standard curve. The samples (duplicates) 
in a volume of 25 μl were incubated for 30 min at 37°C with the BCA reagent, composed 
of solution A (sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium 
tartrate in 0.1 M sodium hydroxide) and solution B (4% cupric sulfate). Absorbance at 550 
nm was measured in the Wallac 1420 Victor 2 multilabel counter. 
 
2.2.1.2 SDS-PAGE and Western Blot 
30 μg of total protein extract reduced by 50 mM of NuPAGE sample reducing agent 
(NuPAGE SRA) were separated by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis) on a NuPAGE Novex TRIS-acetate 3-8% gel according to the 
instruction manual. SDS-gels were then used for Western blot analysis. 
Proteins were transferred to nitrocellulose hybridization transfer membranes using a 
series of increasing voltage gradients (10 V, 20 V, 30 V, 40 V for 10 min each, and 50 V 
for 1 h). 
Blotted membranes were blocked for 1 h with 5% BSA in TRIS buffer containing 0.05% of 
Tween-20 (TBST), incubated with rabbit anti-EGFR antibody (1:1000) diluted in 5% BSA 
in TBST overnight at 4°C with gentle agitation. The day after, the membranes were 
washed with TBST buffer 3 times for 5 min and the membranes were then incubated with 
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horseradish peroxidase (HRP)-coupled anti-rabbit antibody (1:8000) diluted in blocking 
solution for 1 h. After three washings with TBST, the bound antibody was visualized using 
chemiluminescent HRP substrate. Signals were detected in a Chemi-Doc XRS 
luminescence detection system. To verify equal amounts of proteins in each loaded 
sample, the membranes were stained afterwards with anti-actin antibody. For this 
purpose, the membranes were stripped by incubation in stripping buffer for 20 min at RT 
and washed and blocked as described above. The primary mouse anti-actin antibody and 
the HRP-coupled anti-mouse antibody were used at a 1:1000 dilution and 1:8000 dilution, 
respectively. 
 
2.2.2 Cell biological methods 
 
2.2.2.1 Cell culture conditions 
Cells were cultivated under standard cell culture conditions at 37°C in a humidified 
atmosphere of 5% CO2. The human PDAC cells AsPC-1 and BxPC-3 and the human 
mammary carcinoma cells MDA-MB-468 and MCF7 were grown in RPMI-1640 medium 
supplemented with 10% fetal calf serum (FCS). The human PDAC cells Capan-1 were 
grown in IMDM medium supplemented with 20% FCS, PANC-1 in high glucose (4.5 g/l) 
DMEM supplemented with 10% FCS and MIA PaCa-2 in DMEM/F-12 medium with 
Glutamax supplemented with 10% FCS and 2.5% horse serum. 
For sub-cultivation, medium was removed, cells were washed twice with PBS, and treated 
with a 0.25% Trypsin-EDTA solution until they had detached from the dish. The enzyme 
was inhibited by addition of medium in which the cells were subsequently resuspended. 
When necessary, cells were counted in a Neubauer counting chamber and plated in the 
desired concentration into a new dish. 
 
2.2.2.2 Cryoconservation 
For cryoconservation, eukaryotic cells were detached as described above, centrifuged 
(1,200 x g for 2 min at RT), resuspended in freezing medium (1-5 x 106 cells/ml) and 
aliquoted into storage vials. Vials were placed in an freezing box in a -80 °C freezer 
overnight and finally stored in liquid nitrogen. 
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2.2.2.3 Revitalization 
For revitalization, cryoconserved cells were quickly thawed in a 37°C water bath after 
being removed from liquid nitrogen. Then, cells were transferred to 10 ml pre-warmed 
medium and centrifuged (1,200 x g for 2 min at RT). After supernatant removal, cells were 
resuspended in ~3-5 ml of proper medium and transferred to a 25 cm2 or 75 cm2 cell 
culture flask. Subsequently, cells were allowed to attach overnight (37°C, 5% CO2, 95% 
humidity) and medium was changed the next day. 
 
2.2.2.4 In vitro binding assay to PDAC cells for Cetuximab NIRF conjugates 
To analyze the binding of Cetux-Alexa-647 to AsPC-1 and MIA PaCa-2 cells, 2 x 105 
tumor cells were seeded on coverslips in 24 wells plates. After 24 h the medium was 
removed, cells were washed once with PBS and incubated with 10 μg/ml of Cetux-Alexa-
647 diluted in the culture medium for 1 h at 37°C. Afterwards, cells were washed three 
times with PBS to remove unbound probe and fixed with 4% paraformaldehyde (PFA) for 
10 min washed with PBS and mounted in Prolong Gold Antifade Reagent with DAPI, in 
order to stain the nuclei. Cells were analyzed by NIRF microscopy using settings listed in 
Table 6 of section 2.2.5.1. 
To analyze the binding of Cetux-800CW to AsPC-1 cells, 2 x 105 tumor cells were seeded 
in ibidi µdishes and incubated either with 10 μg/ml of Cetux-800CW diluted in culture 
medium or with medium only, for 1 h at 37°C. After 2 washes with PBS, cells were fixed 
with 4% PFA for 10 min, washed with PBS and mounted in Prolong Gold Antifade 
Reagent with DAPI. ibidi chambers were scanned with Odyssey infrared imaging system. 
Fluorescence intensity was detected by 800 nm channel in a raster mode with a resolution 
of 21 μm. 
 
2.2.2.5 Cell preparation for implantation 
One day before implantation, AsPC-1 and MIA PaCa-2 cells were sub-cultivated to 
achieve the cells in an exponential growth phase. On the day of implantation, cells were 
rinsed with PBS, detached as described above (section 2.2.2.1), and washed twice with 
corresponding culture medium. The cell number was determined using a Neubauer 
chamber and suspension volumes containing 1 x 106 cells were centrifuged at 1,200 x g 
for 2 min at RT. Right before the implantation, supernatant was removed and cell pellet 
was resuspended in 20 μl of PBS. 
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2.2.3 In vivo experiments 
All animal experiments were approved by the administration of Lower Saxony (Germany). 
Animals were handled according to the guidelines issued by the animal protection (license 
no. 33.9-42502-04-13/1085). NIRF imaging was performed on 10 to 20 weeks old male 
athymic nude mice strain NMRI-Fox1nu/nu and Erlotinib/Cariporide treatment was 
performed on 9 weeks old male athymic nude mice strain CD1-Fox1nu/nu 
The mice were maintained in the animal facility of the University Medical Center of 
Göttingen in a sterile environment in individually ventilated cages and allowed food and 
water ad libidum. Cages, bedding, and water were autoclaved and the food was gamma 
irradiated. One week before starting the optical imaging experiments, mice received low 
fluorescence food to reduce the autofluorescence of gut and stomach. 
  
2.2.3.1 Orthotopic PDAC mouse models 
For orthotopic transplantation mice were anesthetized by intraperitoneal (i.p.) injection of 
15 mg⁄ kg xylazine and 75 mg/kg ketamine dissolved in PBS. The skin was disinfected, a 
median laparotomy was performed and the pancreas was exposed by applying gentle 
traction to the stomach. 1 x 106 cells in 20 μl of PBS were taken up with an insulin syringe 
with an integrated needle (30G) and cells were implanted into the head of the pancreas. 
The peritoneum was then closed first with continuous suture whereas the skin was closed 
with interrupted stitches, using 4/0 Vicryl in both cases. Mice were kept on a heating plate 
at 37°C and monitored until recovery from anesthesia. For analgesia, mice received 
Rimadyl (Carprofen; 5mg/kg) i.p. during surgery and Metamizole (1.33 mg/ml) in drinking 
water, for two days before and for three days after surgery. Recovered animals were 
inspected and weight three times a week for tumor formation, the occurrence of jaundice 
and general health conditions as well as weight loss.  
Due to the deep location of the pancreas within the body of the animal, it is not possible to 
follow progressively tumor growth by external palpation in PDAC mouse models. 
Consequently, the criteria to sacrifice the mice were based on the loss of weight 
exceeding 20% of the initial weight lasting more than two days. Moreover, typical 
symptoms of PDAC such as jaundice and the general health condition of the mice were 
also carefully evaluated and taken into consideration. Animals were sacrificed with an 
overdose of CO2 and cervical dislocation, and autopsies were performed. During autopsy, 
pancreatic tumors were excised together with stomach and duodenum, and tumor sizes 
were measured by a caliper. Under the assumption that the tumor shape is ellipsoid, the 
tumor volume was calculated according to the formula: volume [mm3] = 0.5 x (length [mm] 
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x width [mm] x height [mm]). Moreover, peritoneal organs, lymph nodes and lungs were 
excised, analyzed as for the presence of macroscopic metastases, and finally fixed in 4% 
formalin in PBS. 
 
2.2.3.2 NIRF fluorescence imaging 
AsPC-1 and MIA PaCa-2 tumor bearing nude mice were used for in vivo and ex vivo 
fluorescence imaging ~30 and ~90 days after tumor implantation, respectively.  
Mice were anesthetized with 0.8-1 % vaporized isoflurane and each mouse received 
intravenously (i.v.) either a single dose of Cetux-Alexa-647 or the combination of Cetux-
Alexa-647 and the control isotype hIgG-Alexa-750 (25 µg each in 150 µl of 0.9% NaCl) 
with an insulin syringe with integrated needle (30G x ½). In vivo and ex vivo imaging was 
performed by Optix MX2 and IVIS Spectrum scanners. 
 
 Optix MX2 
NIRF scans 
Optix MX2 system was used for detection and quantification of Cetux-Alexa-647 and the 
control hIgG-Alexa-750 fluorescence signals in vivo over the upper abdomen of the living 
animals as well as ex vivo of the mice with open abdominal cavity and the explanted 
organs. 
This system uses a fixed pulsed lasers as an illumination source, and works in reflection 
mode applying a raster acquisition scheme. It utilizes a single photon counting detector for 
measuring the number of photons coming in response to a pulsed excitation for each 
raster point. As illustrated in Figure 8, the resulted curve named temporal point spread 
function (TPSF) represents the distribution of the number of photons coming from a raster 
scan point over time. 
For in vivo analysis, before (prescan), as well as at 24 h and 48 h after the injection of the 
fluorescent probes, mice were anesthetized with 0.8-1% vaporized isoflurane, placed 
inside the imaging device on a table preheated to 37°C, and scanned in vivo over the 
upper abdomen. After 48 h, mice were sacrificed and scanned with open abdominal 
cavity. Subsequently, tumors were excised and tumor sizes were measured with a caliper 
as described above (section 2.2.3.1). Furthermore, the organs such liver, kidneys, spleen, 
mesentery, as well as lung and lymph nodes, were isolated and imaged together with the 
primary tumors ex vivo. For in vivo and ex vivo acquisition of Cetux-Alexa-647 and hIgG-
Alexa-750 derived fluorescence shown in the Table 2 were used: 


















Alexa Fluor 647 635 nm 670 ± 20 nm  in vivo scans   100 µW 1 sec 1 mm 
Alexa Fluor 750 / 
IRDye 800CW 
730 nm ≥ 770 nm  
ex vivo / in 
vitro scans   
100 µW 0.5 sec 1.5 mm 
 
Table 2 : Lasers, filters and acquisition settings of Optix MX2 
 
Optix-MX2 was also used to scan mice that received Cetux-800CW for the fluorescence- 
guided dissection. Mice were scan in vivo before (prescan), as well as at 24 h after the 
injection of the fluorescent probe. After the 24 h in vivo scan, mice underwent 
fluorescence-guided dissection (section 2.2.3.4), and then excised organs were also 
scanned ex vivo by Optix-MX2. Settings used for in vivo and ex vivo NIRF imaging of 
Cetux-800CW are shown in Table 2. 
 
Lifetime analysis 
Optix MX2 was also used to measure the LTs of Cetux-Alexa-647 and of hIgG-Alexa-750 
probes in vitro and in vivo. The device calculates the fluorescence LT by linear regression 
(blue line, Figure 8) in the slope of the TPSF obtained for a specific raster point of a scan. 
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Figure 8 : TPSF of one representative raster scan point. TPSF curve, exemplarily shown for one scan 
point selected from a scan of a solution containing a fluorophore, representing the distribution of the number 
of photons over time. The time in nanoseconds (ns) between excitation pulse and detection of fluorescence 
photons is depicted on the x-axis, whereas the fluorescence intensity, in normalized counts (NC), is illustrated 
on the y-axis. From the decay of the curve (blue curve) the fluorescence LT is automatically calculated by 
Optix MX2. 
 
LTs of the fluorescence conjugates Cetux-Alexa-647 as well as of the respective isotype 
control hIgG-Alexa-750 were first determined in vitro. For measurement, 0.05 µg of 
conjugates in 10 μl of the cell culture medium were dropped on a petri dish and scanned 
with Optix MX2 using settings indicated in Table 2. To measure the in vivo fluorescence 
LTs of the injected probes, Optix MX2 scans of the mice 24 h after the double-injection of 
Cetux-Alexa-647 and hIgG-Alexa-750 over the primary tumor or the liver, respectively, 
were considered. 
 
 IVIS Spectrum 
IVIS Spectrum uses a continuous wave quartz halogen lamp that simultaneously and 
uniformly illuminates the whole animal. Then, the light is spectrally filtered through 10 
narrow band excitation filters and 18 narrow band emission filters. 
For the in vivo analysis, isoflurane anesthetized mice were placed inside the IVIS imager 
and 2D fluorescence imaging of the whole body of the animal was performed in epi-
fluorescence mode, before (prescan) as well as 24 h and 48 h after probe injection. Ex 
vivo scans of animals with opened abdominal cavity and of the excised organs were also 
performed. The detection of Alexa Fluor 647 and Alexa Fluor 750 fluorescence was 
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IVIS Spectrum 

















670-690 nm  
in vivo / ex 
vivo scans   





790-810 nm       
 
Table 3: Lasers, filters and acquisition settings of IVIS Sprectrum. 
 
Moreover, since IVIS Spectrum enables the simultaneous visualization of multiple 
fluorophores differing in emission wavelength, by spectral-unmixing analysis. This was 
used to overlay Cetux-Alexa-647 and hIgG-Alexa-750 fluorescence imaging maps over 
the same mouse. 
 
2.2.3.3 Co-registration of fluorescence tomography and CT data 
AsPC-1 tumor bearing mice (n=2) received a single i.v.   of Cetux-Alexa-647 and he 
control hIgG-Alexa-750 (25 µg each in 150 µl of 0.9% NaCl) 24 h prior to imaging and 
were sequentially scanned with QuantumFX micro CT (µCT) and IVIS Spectrum, and the 
data from both devices were co-registered. Since normal pancreas and pancreatic tumors 
in mice do not show uptake of intravenously injected iodine containing CT contrast agent, 
animals were fed for 24 h with pellets soaked with water-diluted oral iodine containing 
contrast agent (Imeron 300, diluted 1:10) to highlight the intestinal tract. Furthermore, 
mice received 200 µl of undiluted Imeron 300 orally by gavage shortly before the CT scan 
to display the stomach. 
 
 µCT 
First, the anatomical structures of the mice were as determined by µCT. Mice were 
anesthetized with 0.8-1.0% isoflurane, fixed ventral side up in the imaging shuttle and 
scanned with Quantum FX. This device is a low dose cone beam in-vivo µCT, especially 
designed for imaging of small animals such as mice. The following parameters were used 
for data acquisition: field of view 73 x 73 mm2, tube voltage 70 kVp, tube current 200 µA 
and a total acquisition time of 17 s resulting in 3D data sets with a reconstructed voxel 
size of 150 x 150 x 150 µm3. 
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 3D Fluorescence Imaging Tomography (FLIT) imaging 
After the µCT scan, the imaging shuttle with anaesthetized mice was carefully moved 
inside the IVIS Spectrum device and imaged using the 3D FLuorescence Imaging 
Tomography (FLIT) mode, which enables first the reconstruction of the surface 
topography by using a structural illumination approach. Then, the 3D location of the 
fluorescent sources were as obtained by scanning the mouse ice in a transillumination 
setup using settings for the detection of either Alexa-Fluor-647 or and Alexa-Fluor-750 as 
indicated in Table 3. 
In order to perform the fusion of the data obtained, the µCT images were exported as 
DICOM files and loaded together with the FLIT data into the Living Image software. The 
fiducial markers within in the imaging shuttle, allowed the reciprocal location of the data 
obtained with the two devices. 
 
2.2.3.4 Fluorescence-guided dissection 
Fluorescence-guided dissection of AsPC-1 tumor bearing mice was performed ~30 days 
after cell injection. Isoflurane anesthetized mice were i.v. injected with Cetux-800CW (25 
µg in 150 µl of 0.9% NaCl) and sacrificed 24 h later. Section was guided with the Quest 
Spectrum clinical system for FGS equipped with a wide field lens for open surgery and a 
hand-held camera configured for the specific detection of IRDye 800CW fluorescence, 








IRDye 800CW 785 nm > 808 nm 
 
Table 4: Laser and filters settings of Quest Spectrum. 
 
IRDye 800CW fluorescence and white light images were acquired simultaneously by the 
camera, allowing for an automatic depicted overlay of the two. 
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2.2.3.5 Schedule and evaluation of Cariporide-Erlotinib treatment 
Mice implanted with AsPC-1 cells were treated with Cariporide or Erlotinib alone or a 
combination of them. At day 10 after implantation mice were randomly divided in four 
groups: 
- Group 1: Erlotinib (50 mg/kg, 8.3 µl/gr BW, gauge) dissolved 6% Captisol in water 
applied orally by gavage  
- Group 2: Cariporide (3 mg/kg, 3 µl/gr BW, i.p. ) dissolved in 0.9% NaCl and given 
i.p.  
- Group 3: a combination of Erlotinib (50 mg/kg, 8.3 µl/gr BW, gauge) and 
Cariporide (3 mg/kg, 3 µl/gr BW, i.p. ) given as in groups 1 and 2. 
- Group 4: control mice that received a solution of 6% Captisol orally by gavage and 
0.9 % NaCl i.p. with volumes corresponding to the volumes applied for Cariporide 
and Erlotinib. 
and each treatment was performed daily for 20 days. 
At day 30 post implantation, animals were sacrificed as described above (section 2.2.3.1) 
and general status of the mice (presence of cachexia or jaundice) were documented. 
Then, the skin and peritoneum were opened and the primary tumor was carefully checked 
as for general morphology and macroscopically invasion in the stomach and duodenum. 
Afterwards, the tumor mass was measured as described in section 2.2.3.1. 
In addition, peritoneal cavity, diaphragm, mesentery and organs such as liver, spleen, 
mesentery, diaphragm and kidney were analyzed for presence of macroscopic 
metastases. Metastases were identified, measured in size and counted. 
For the microscopically evaluation of the invasion of the primary tumor into stomach and 
duodenum, primary tumors were cut at 4 different levels (distance: ~100 µm) and stained 
by IHC for EGFR as described in section 2.2.4.2. The four sections were analyzed by two 
researchers for infiltration of tumor cells in stomach and duodenum, which was then 
classified as follows: - (no infiltration), L (low infiltration), M (medium infiltration) and H 
(high infiltration). The highest grade obtained out of the four slides was considered. 
To assess the tumor mass at treatment starting point, one additional group of mice was 
implanted with AsPC-1 cells and sacrificed at day 10 after transplantation. The small 
tumor mass developed was measured as described above (section 2.2.3.1). 
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2.2.3.6 Tissue preparation 
Dissected tumors or organs were fixed in 4% formalin in PBS overnight and placed in 
Tissue Tek cassettes. The tissues were automatically dehydrated in an ethanol series and 
paraffinized in a tissue processor apparatus as indicated in Table 5. 
 
repetition cycles time applied substance 
   
1 1 h 30 min  60% Ethanol 
2 1 h 30 min 75% Ethanol 
2 1 h 30 min 95% Ethanol 
2 1 h 30 min 100% Ethanol 
2 1 h 30 min Xylol  
2 1 h 30 min Paraffin 
 
Table 5: Dehydration scheme for tissue processing. 
 
Sections of the paraffin-fixed tumors and organs were obtained using made with the 
microtome in 2.5 μm thickness. Sections were dried overnight at RT, and stored at RT 
until staining was performed. 
 
2.2.4 Histology of tissue sections 
 
2.2.4.1 Hematoxylin-Eosin (HE) staining 
Tissue sections were deparaffinized by heat at 60°C for 30 min, followed by two washes 
with xylol for 7 min each. Then, the sections were rehydrated using propanol (5 min) and 
decreasing concentrations of ethanol (95%, 75% and 60%) for 5 min each, followed by 
one wash with demineralized water. The Hematoxylin staining of cell nuclei was done for 
5 min and after washing with demineralized water for 5 min, the cell cytoplasm of the cells 
was stained with Eosin G (1:10 dilution in H2O) for 5 min. After staining, sections were 
washed shortly with demineralized water and dehydrated with increasing concentrations 
of ethanol (60%, 75% and 95%) and once in propanol, for 5 min each. Sections were then 
cleared twice in xylol (5 min each) and mounted in hydrophobic mounting medium 
(DePex). 
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2.2.4.2 Immunohistochemistry staining of tissue sections  
For immunohistochemistry (IHC), tissue sections were deparaffinized and rehydrated as 
described in section 2.2.4.1. Antigen retrieval was performed by incubation in target 
retrieval solution (modified citrate buffer from Dako, pH 6) at 90°C in a steamer for 20 min. 
Sections were cooled down with cold DEPC water for 5 min and washed once with TBS 
for 5 min. The endogenous peroxidase was inhibited by incubation with 3% H2O2 for 10 
min and washed twice with TBS (5 min). 
After incubation with SEA BLOCK blocking buffer for 20 min at RT, sections were directly 
stained overnight at 4ºC with either the monoclonal rabbit anti-human EGFR antibody 
(SP9, 1:500) or the polyclonal rabbit anti-mouse alpha-smooth muscle actin (α SMA) 
antibody (1:500) diluted in antibody diluent. Sections were washed and further stained 
with one drop of undiluted anti-rabbit-HRP antibody (Histofine Simple Stain Max PO) for 
60 min at RT. After two washes with TBS (5 min each), sections were incubated with 3-
Amino-9-ethylcarbazole (AEC) peroxidase substrate for 30 min at RT, washed once with 
distilled water and counterstained with Hematoxylin for 20 sec. Following counterstaining, 
the sections were rinsed briefly in demineralized water and then in running tap water for 5 
min. Finally, sections were mounted with aqueous mounting medium (Aquatex) and dried 
overnight at RT. 
 
2.2.4.3 Collagen staining 
For collagen I & III staining, Picro-Sirius Red staining kit was used. Tumor sections were 
deparaffinized and rehydrated as described in section 2.2.4.1. Then, Hematoxylin was 
used to stain the nuclei of the cells for 5 min, and after one wash with demineralized water 
for 5 min, sections were further immersed in solution A (phosphomolybdic acid) for 2 min, 
washed briefly with demineralized water and placed first into solution B (Picro-Sirius Red 
F3BA stain) for 60 min and then directly into solution C (0.01 N Hydrochloride Acid) for 2 
min. Sections were then dehydrated, cleared in xylol and mounted as described in section 
2.2.4.1. 
HE and colorimetric staining of tumor tissue were evaluated with Axiovert 200M 
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2.2.5 NIRF analysis of tumor and metastases sections 
 
2.2.5.1 Immunofluorescence and NIRF microscopy 
Immunofluorescence was performed on tumor tissue derived from animals co-injected 
with Cetux-Alexa-647 and hIgG-Alexa-750 and employed for NIRF imaging. 
Sections were deparaffinized, rehydrated and antigen retrieval was performed as 
described in section 2.2.4.1. Autofluorescence was blocked with TRIS-glycine buffer for 
10 min at RT, sections were washed twice with TBS (5 min each) and incubated with SEA 
BLOCK blocking buffer for 20 min. Then, sections were directly incubated overnight with 
rabbit-anti human EGFR antibody (SP9, 1:500) diluted in antibody diluent, washed twice 
with TBS (5 min each) and incubated at RT for 1 h with the secondary anti-rabbit-Alexa-
Fluor 488 antibody (1:400). Afterwards, sections were washed twice with TBS (5 min 
each) and counterstained with DAPI (4 µg/ml) for 10 min, washed once with TBS (5 min) 
and mounted with aqueous mounting medium (Aquatex) and dried overnight at 4ºC. 
For examination of Cetux-Alexa-647 and hIgG-Alexa-750 fluorescence signal on human 
AsPC-1 and MIA PaCa-2 tumor cells and PDAC tumor tissues, the fluorescence 
microscope Axiovert 200M equipped with a NIR-sensitive ORCA-ER digital camera was 
used. Filter settings are illustrated in Table 6. Images obtained were analyzed using 
Image J [85]. 
 
Fluorescence microscopy 
   
 Excitation  filter  Emission filter 
Alexa Fluor 647 640 ± 15 nm 690 ± 25 nm  
Alexa Fluor 750 708 ± 37.5 nm  809 ± 40.5 nm  
Alexa Fluor 488 450-490 nm  515-565 nm  
DAPI 365 ± 12.5 nm  445 ± 25 nm  
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2.2.5.2 Odyssey scans of tissue sections 
For analysis of primary tumor and metastatic organs from AsPC-1 mice undergoing 
fluorescence-guided dissection, sections were deparaffinized and rehydrated as described 
in section 2.2.4.1. Sections were then washed once with TBS (5 min) before, directly 
mounted with aqueous mounting medium (Aquatex) and dried overnight at 4ºC. Cetux-
800CW derived fluorescence signal on tumor tissue and metastases in different organs, 
was evaluated in the Odyssey infrared imaging system. Fluorescence intensity was 
detected by a 800 nm channel in a raster mode with a resolution of 42 μm. 
 
2.2.6 Statistical analysis 
The significance was analyzed by two-tailed unpaired Student’s t-test using Past [86] 






3.1 Orthotopic human PDAC mouse models 
In order to select the most suitable models for preclinical evaluation of novel NIRF 
imaging and therapeutic strategies, different PDAC mouse models obtained by orthotopic 
implantation of well characterized human pancreatic tumor cell lines [87] were analyzed in 
detail for tumor growth, time of development and grade of invasion into the surrounding 
organs. Moreover, morphological features such as differentiation grade and desmoplastic 
reaction were investigated. 
 
3.1.1 Growth characteristics and time of tumor development  
Five different PDAC mouse models were established by orthotopic implantation of 1 x 106 
human pancreatic tumor cells into the head of the pancreas of athymic male nude mice. 
Because human pancreatic cancer includes a multitude of histomorphological subgroups, 
AsPC-1, MIA PaCa-2 and PANC-1 cell lines as undifferentiated- or poorly differentiated-, 
BxPC-3 as moderately differentiated- and Capan-1 as differentiated cell lines were chosen 
to be applied. 
Orthotopic transplantation into the head of the pancreas of all five human PDAC cell lines 
resulted in local tumor growth and in most cases in tumor invasion into the duodenum and 
stomach. However, in each PDAC mouse model, depending on the cell line implanted, a 
distinct pattern of tumor growth and progression occurred. Therefore, mice were sacrificed 
at different time points after cell transplantation, defined as time of tumor development 
and equating to the time between the day of implantation and the endpoint of the 
experiment (Figure 9). As PDAC tumors are hardly detectable by visual inspection, the 
time for sacrifice was chosen based on the presence of typical symptoms of PDAC such 
as weight loss of more than 20% of the initial weight, apathetic behavior or jaundice. 
Due to a fast tumor growth rate of AsPC-1 in vivo (poorly differentiated), transplanted mice 
(n=6) were sacrificed as early as 4 to 5 weeks after cell transplantation, whereas mice that 
received the other two poorly differentiated cell lines, MIA PaCa-2 (n=9) and PANC-1 
(n=4), were sacrificed later, between 10 and 16 weeks and between 12 and 20 weeks, 
respectively. 12 to 13 weeks was the time required for the BxPC-3 xenografts (moderately 
differentiated, n=7) to develop, whereas the well differentiated Capan-1 model (n=10) 
showed symptoms related to tumor development between 13 to 19 weeks after cell 
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transplantation. Representative images of the macroscopical appearance of the different 
tumors after dissection are shown in Figure 9. AsPC-1 and BXPC-3 transplanted mice 
formed the smallest tumor lesions compared to the other PDAC mouse models with 
average tumor volumes of 122 ± 93 mm3 and 193 ± 111 mm3, respectively, followed by 
the PANC-1 mouse model, which is characterized by an average tumor volume of 294 ± 
194 mm3. Instead, MIA PaCa-2 and Capan-1 cells developed much larger tumor masses 
in the range of 845 ± 428 mm3 and 1183 ± 812 mm3, respectively. Furthermore, in all 
PDAC models tumors usually invaded into the duodenum and stomach (Figure 9), 
resulting in complications such as stomach and/or duodenum obstruction, accompanied 
by rapid weight loss. The tumor take rate, defined as the percentage of tumors that 
develop after orthotopic cell transplantation into mice, was 100% for AsPC-1, Capan-1 
and BxPC-3 mouse models, whereas MIA PaCa-2 and PANC-1 cells revealed slightly 
lower tumor take rates of 90% and 75%, respectively. 
 
Figure 9: Characteristic features of primary tumor growth of human orthotopic PDAC mouse models. 
Time of tumor development, defined as the time between the day of implantation and the endpoint of the 
experiment, tumor take rate, defined as percentage of tumors that develop after orthotopic injection into mice, 
tumor volume and stomach/duodenum infiltration at the time of section are depicted for each PDAC xenograft. 
Representative images of the macroscopic morphology of the primary tumors invading into the stomach and 
duodenum (black arrow) are also depicted. 
 
3.1.2 Histological features and desmoplastic reaction of primary tumors developed 
in PDAC mouse models  
Primary tumors obtained from the five PDAC models were further analyzed histologically 
by HE and immunohistochemical staining of paraffin tumor sections (Figure 10). 
Tumors from AsPC-1, MIA PaCa-2 and PANC-1 were diagnosed by HE staining (Figure 
10, left column) as poorly differentiated PDAC, all with a completely homogenous and 
unorganized pattern of tumor cells. BxPC-3 tumors showed a moderately differentiated 
morphology with cells arranged in large round clusters (yellow arrow). Instead, tumor cells 
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organized in duct-like clusters (yellow arrow) were found in the well differentiated Capan-1 
tumors. 
In order to assess in each mouse model the development of a desmoplastic reaction, a 
hallmark of human PDAC, paraffin sections of primary tumors were 
immunohistochemically stained with an antibody directed against α-SMA, a marker of 
activated pancreatic stellate cells, and histochemically stained with Sirius Red, for the 
detection of all types of collagen (I, II and III).  
Each primary tumor obtained from the different PDAC mouse models revealed a distinct 
α-SMA staining pattern (Figure 10, middle column). All tumors showed reddish staining of 
elongated and myofibroblast-like stroma cells located among tumor cells, indicating the 
presence of activated PSCs. No differences in the amount of α-SMA positive cells were 
found between the tumors, however, in poorly differentiated primary tumors of the AsPC-
1, MIA PaCa-2 and PANC-1 mouse models, α-SMA positive cells appeared 
homogenously dispersed between tumor cells. By contrast, in moderate to well 
differentiated BxPC-3 and Capan-1 tumors, α-SMA positive cells seemed to be more 
grouped around clusters of tumors cells.  
Sirius Red staining (Figure 10, right column) revealed that only primary tumors of the 
Capan-1 model induced a large amount of collagen deposition around the duct-like tumor 
structures. Comparable collagen fibers surrounding the clusters of tumors were found in 
BxPC-3 mouse model, although containing less amounts of collagen. In contrast, the 
poorly differentiated tumors (MIA PaCa-2, AsPC-1 and PANC-1) were composed of a 
much more unorganized collagen deposition around the undifferentiated tumor cells. In 





Figure 10: Paraffin sections of representative PDAC primary tumors, stained with HE (left), with an 
antibody directed against α-SMA (middle) and with Sirius Red kit for collagen (right). HE staining 
revealed differences in the grade of differentiation of the primary tumors. AsPC-1, MIA PaCa-2, PANC-1 show 
a poorly differentiated morphology, whereas BxPC-3 and Capan-1 reveal a moderately- and well- 
differentiated morphology, respectively. Yellow arrows indicate the presence of clusters of tumor cells in 
BxPC-3 and Capan-1 models. α-SMA staining showed activated PSCs (reddish staining; yellow arrows), 
dispersed all over the poorly differentiated tumors AsPC-1, MIA PaCa-2, PANC-1 and located around the 
clusters of the differentiated tumor BxPc-3 and Capan-1 cells. Sirius Red staining highlights elongated 
collagen fibers (strong red) in between the poorly differentiated cells and around the clusters of differentiated 
tumor cells. Note, that the same peri-tumoral areas are stained for α-SMA and Sirius Red in each mouse 







Taken together, five different PDAC models were established, each characterized by a 
distinct tumor growth rate and invasion behavior, independent of the grade of tumor 
differentiation. Moreover, each model revealed different characteristic morphological 
features such as grade of differentiation and development of desmoplastic reaction (the 
amount of collagen deposition and presence of PSC). 
 
3.2 NIRF labeled Cetuximab targeting EGFR as a tool for fluorescence-guided 
surgery 
Next, two of the orthotopic human PDAC mouse models were chosen to preclinically 
analyze the suitability of the already clinically used antibody Cetuximab, targeting human 
EGFR. The antibody was conjugated to fluorescence dyes in the NIR range to visualize 
primary PDAC tumors and detect small metastases in live mice by NIRF imaging and 
during fluorescence-guided dissection. 
 
3.2.1 Characterization of PDAC cell lines for EGFR expression 
In order to identify two human PDAC cell lines with high and low EGFR expression to be 
applied in vivo for NIRF imaging, the five human PDAC cell lines were analyzed for 
expression levels of EGFR protein by Western blotting. For this, 30 µg of total protein 
extract from each cell line was separated via SDS-PAGE and analyzed for the presence 
of bands at the expected molecular weight of 170 kDa, using a polyclonal anti-EGFR 
antibody (#2232). As positive and negative controls, we used MDA-MB-468 and MCF7 
breast cancer cell lines, respectively. 
As illustrated in Figure 11, a strong expression of EGFR was found in AsPC-1 and BxPC-
3 cells, whereas a moderate and low expression of EGFR was observed in PANC-1 and 
MIA PaCa-2 cells, respectively. Capan-1 cells did not show any EGFR expression by 
Western blot analysis. β-actin expression was used as a loading control and showed 





Figure 11: Expression of EGFR in PDAC cell lines. (a) Western-blot analysis shows high EGFR expression 
(170 kDa band) in AsPC-1 and BXPC-3 cells, moderate expression in PANC-1 cells, low expression in MIA 
PaCa-2 cells, and no expression in Capan-1 cells. MDA-MB-468 and MCF7 cells were used as positive (+) 
and negative (-) control, respectively. Staining of β-actin revealed a comparable amount of total protein loaded 
for all samples. 
 
3.2.2 In vitro binding studies of NIRF labeled Cetuximab to EGFR expressing PDAC 
cells  
NIRF labeled Cetuximab was used as follows: i) coupled to Alexa Fluor 647, one of the 
most common preclinically used NIRF dyes (Cetux-Alexa-647) at a dye-to-protein ration of 
6.7, and ii) coupled to IRDye800CW (Cetux-CW800) at a dye-to-protein ratio of 0.6. For in 
vivo experiments, human IgG1 coupled to Alexa Fluor 750 dye (hIgG-Alexa-750) at a dye-
to-protein ratio of 5.3 was used as isotype control.  
In order to characterize the binding of Cetux-Alexa-647 in vitro to high EGFR expressing 
(AsPC-1) and low EGFR expressing (MIA PaCa-2) cells, the cells were grown on 
coverslips and incubated for 1 h at 37ºC with 10 μg/ml of Cetux-Alexa-647. Figure 12a, 
left) shows that incubation of AsPC-1 cells with Cetux-Alexa-647 resulted in a strong 
plasma membrane and cytoplasmatic cell staining pattern indicating partial internalization 
of the conjugate. In comparison, MIA PaCa-2 cells incubated with Cetux-Alexa-647 
showed a comparable plasma membrane and cytoplasmatic staining pattern, but with 
much lower intensity (Figure 12a, right). 
Furthermore, binding of Cetux-800CW (10 μg/ml) to AsPC-1 was tested in vitro in cells 
grown on ibidi μdishes. After 1 h of incubation with the conjugate at 37ºC, cells were fixed 
and scanned by the Odyssey imager, which allows the detection of NIR fluorescence 
signals with a resolution lower than a fluorescence microscope. Scans revealed high 
fluorescence signals over the AsPC-1 cells incubated with Cetux-800CW (Figure 12b, left) 
in comparison to control cells incubated without the conjugate (Figure 12b, right), which 




Figure 12: In vitro binding of Cetux-Alexa-647 and Cetux-800CW to PDAC cells. (a) Representative 
pictures of fixed AsPC-1 and MIA PaCa-2 cells incubated with Cetux-Alexa-647. Higher fluorescence signals 
on the membrane and within the cytoplasm of AsPC-1 cells were found than at the cell membrane and within 
the cytoplasm of MIA PaCa-2 cells (red). The nuclei are counterstained with DAPI (blue). Scale bars represent 
50 µm. (b) Odyssey scan of fixed AsPC-1 cells incubated with Cetux-800CW (left) shows higher fluorescence 
signals in comparison to the low autofluorescence obtained over the AsPC-1 cells incubated with medium only 
(right). 
 
Taken together, these results show that the NIRF labeled Cetuximab conjugates, Cetux-
Alexa-647 and Cetux-800CW, bind to the high EGFR-expressing AsPC-1 and to the low 
EGFR-expressing MIA PaCa-2 cells in vitro. This confirms that AsPC-1 and MIA PaCa-2 
PDAC mouse models are suitable for the evaluation of labeled Cetuximab as a tool for in 
vivo NIRF imaging. 
 
3.2.3 Characterization of EGFR expressing orthotopic PDAC xenografts 
AsPC-1 and MIA PaCa-2 orthotopic PDAC models were chosen as the most suitable 
mouse models to validate the binding of Cetux-Alexa-647 and Cetux-800CW to PDAC 
cells in vivo and to assess their suitability for NIRF imaging in vivo and during 
fluorescence-guided surgery.  
Growth pattern and metastatic behavior of AsPC-1 and MIA PaCa-2 xenografts were 




3.2.3.1 Tumor growth, invasion and metastatic spread of ASPC-1 and MIA PaCa-2 
mouse models 
Mice transplanted with AsPC-1 cells, were sacrificed within 4 to 5 weeks after 
implantation, a time point when mice developed symptoms related to PDAC growth. At 
this time, primary tumors showed average tumor volumes of 122 ± 93 mm3, with invasion 
into the stomach and duodenum (Figure 9). Moreover, the AsPC-1 model showed a 
massive tumor spread to different sites and organs adjacent to the pancreas such as the 
left liver lobe, spleen, peritoneum and mesentery (Figure 13a-c). AsPC-1 tumor nodules 
were also found at the site of surgical incision (Figure 13d) where occasionally a large 
tumor mass developed. 
Unlike AsPC-1, orthotopically transplanted MIA PaCa-2 mice were sacrificed much later, 
within 10 to 16 weeks after transplantation. At this time, tumor volumes in the range of 845 
± 428 mm3 were much larger than the ones observed in the AsPC-1 mouse model (Figure 
9). Similar to AsPC-1, invasion of the MIA PaCa-2 primary tumor into the stomach and 
duodenum was macroscopically observed (Figure 9). However, in contrast to the highly 
aggressive model AsPC-1, MIA PaCa-2 primary tumors did not form metastases in the 
peritoneal organs, but commonly infiltrated, in almost 90% of the mice, the liver hilus 
(Figure 13e), occasionally causing jaundice (Figure 13f). 
 
 
Figure 13: Macroscopic appearance of the metastatic spread of orthotopic AsPC-1 and MIA PaCa-2 
xenografts in nude mice. (a-d) Representative macroscopic images of peritoneal organs from AsPC-1 tumor 
bearing mice during section performed ~30 days after cell transplantation (n=6). White arrows point to 
metastases in the (a) left liver lobe, (b) spleen (c) mesentery as well as to (d) tumor mass grown at the 
surgical scar. (e, f) Representative autopsy findings in MIA PaCa-2 xenografts during section performed ~90 
days after orthotopic transplantation (n= 9). (e) Representative macroscopic image of metastases and 
infiltration of tumor cells into the liver portal triad, leading to biliary obstruction (arrow). (f) Evident jaundice of 
the mouse as a consequence of the biliary obstruction. 
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3.2.3.2 Characterization of EGFR expression in tumor tissue obtained from PDAC 
mouse models 
Both, AsPC-1 and MIA PaCa-2 primary tissue sections obtained from tumors that 
developed in each PDAC mouse model were stained for the expression of the human 
EGFR by immunohistochemistry. Figure 14a,b shows relatively homogenous strong 
EGFR staining on AsPC-1 tumor cells. In contrast, a heterogeneous EGFR expression 
pattern was found within MIA PaCa-2 tumors (Figure 14c). Here, weak EGFR staining 
was observed in different areas within the primary tumor mass (Figure 14d), whereas 
tumor cells especially in the proximity of the invasion front into the stomach and 
duodenum showed strong staining of EGFR (Figure 14e). Large and central necrotic 
areas, with almost no EGFR staining, were present in both, AsPC-1 and MIA PaCa-2 
primary tumors (black arrows; Figure 14a,c).  
 
Figure 14: EGFR expression on AsPC-1 and MIA PaCa-2 primary tumors. (a-b) Anti-EGFR staining of 
paraffin sections of a primary AsPC-1pancreatic tumor shows relatively homogeneous and strong EGFR 
expression in almost all tumor cells. (c-e) Anti-EGFR staining of the MIA Paca-2 pancreatic tumor shows a 
heterogeneous expression pattern of EGFR in tumor cells. (c) Tumor areas with weak EGFR staining (d) as 
well as areas with high EGFR staining (e) are depicted. Necrotic areas in the center of both tumors are 
indicated in (a) and (c) by black arrows. Scale bars represent 200 µm.  
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Taken together, these results show that AsPC-1 and MIA PaCa-2 mouse models differ not 
only in their tumor growth rates but also show a distinct pattern of metastatic spread in 
peritoneal organs: the AsPC-1 mouse model was highly metastatic whereas the MIA 
PaCa-2 model revealed rare metastatic spread and common infiltration of the liver hilus. 
Therefore, both PDAC models, expressing high and moderate amounts of EGFR protein 
in the tumor, are suitable for the evaluation of the in vivo NIRF imaging approach in 
combination with NIRF labeled Cetuximab to visualize not only the primary tumor but also 
small metastatic lesions. 
 
3.2.4 Characterization of the in vivo binding of Cetux-Alexa-647 in EGFR expressing 
PDAC xenografts 
In order to assess the ability of Cetux-Alexa-647 to visualize EGFR expressing PDAC 
tumors, the fluorescent probe was applied to tumor bearing mice and analyzed by in vivo 
and ex vivo optical imaging. 
 
3.2.4.1 Cetux-Alexa-647 accumulates within primary PDAC tumors in vivo 
Binding of Cetux-Alexa-647 to AsPC-1 and MIA PaCa-2 xenografts was first analyzed in 
vivo. NIRF imaging experiments were performed at distinct time points after 
transplantation, depending on the different tumor growth rates of the two PDAC mouse 
models (described in section 3.1.1). Either 30 days (AsPC-1-tumor bearing mice) or 90 
days (MIA PaCa-2-tumor bearing mice) after transplantation, mice were natively scanned 
with the Optix MX2 (upper abdominal scan) and the IVIS (whole body scan) in order to 
measure the level of autofluorescence background prior to probe injection. Then, Cetux-
Alexa-647 was i.v. injected, either alone (25 µg; data not shown) or in combination with 
the control probe hIgG-Alexa-750 (25 µg of each; n=10 for AsPC-1 and n=7 for MIA 
PaCa-2) and imaging with both devices was performed 24 h and 48 h after probe injection 
to determine the distribution and binding kinetics of Cetux-Alexa-647 and the control. 
Figure 15a shows a series of representative NIRF images of the upper abdomen (white 
rectangle represents the scanned area) of tumor bearing mice taken with the Optix MX2 
before as well as 24 and 48 h after co-injection of Cetux-Alexa-647 and hIgG-Alexa-750. 
Cetux-Alexa-647 derived fluorescence detected in AsPC-1 mice (Figure 15a, upper 
panels) is diffusely localized over the scanned area of the upper abdomen, presumably 
due to the overlap of the signals derived from the primary tumor with the signals from the 
tumor mass grown at the surgical incision right above the primary tumor mass. In 
comparison, Cetux-Alexa-647 derived fluorescence in the MIA PaCa-2 tumor bearing 
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mice (Figure 15a lower panels) had a lower intensity and was clearly localized over the 
center of the upper abdomen where the primary pancreatic tumors are expected to 
develop. In both tumor models the measured fluorescence intensities of Cetux-Alexa-647 
were highest at 24 h and decreased at 48 h after injection. 
 
 
Figure 15: In vivo binding of Cetux-Alexa-647 to AsPC-1 and MIA PaCa-2 primary tumors. (a) 
Representative in vivo Optix MX2 scans of the upper abdominal area (white rectangle) before, 24 h and 48 h 
after co-injection of Cetux-Alexa-647 (left) and hIgG-Alexa-740 (right), 25 µg each, in AsPC-1 (upper panel, 
n=10) and MIA PaCa-2 (lower panel, n=7) tumor bearing mice. Cetux-Alexa-647, but not the control hIgG-
Alexa-750, was detected over the AsPC-1 and MIA PaCa-2 primary pancreatic tumors (T), as well as over the 
tumor mass developed at the surgical scar (T/S) in the AsPC-1 model. Due to the overlap of the two tumor 
masses in the AsPC-1 model (primary tumor and tumor at the scar), average Cetux-Alexa-647 fluorescence 
intensity in the AsPC-1 mice is much higher and more diffuse than the signal obtained in MIA PaCa-2 mice. 
Fluorescence intensities are displayed in normalized counts [NC]. (b) Box plot showing significantly higher 
average fluorescence intensities [NC] measured over the tumor areas at 24 h and at 48 h (*** represent p < 
0.001) than in prescans of both, AsPC-1 and MIA PaCa-2 tumor bearing mice.  
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In contrast, the co-injected control antibody, hIgG-Alexa-750, did not localize to the 
pancreatic tumor sites but showed fluorescence signals only over the liver area. Similar to 
the Cetux-Alexa-647, hIgG-Alexa-750 reached its maximum measured fluorescence 
intensity at 24 h after injection in both mouse tumor models. The native scans (prescan) of 
both mouse models did not show any significant fluorescence signals (Figure 15a). 
As shown in Figure 15b, quantification of the average fluorescence intensities of Cetux-
Alexa-647 over the tumor areas confirmed significantly higher fluorescence intensity in 
both, AsPC-1 and in MIA PaCa-2 mice at 24 h and 48 h compared to values of the 
prescans. 
Although Optix MX2 allows high sensitivity scans in the intensity- and time-domains, this 
non-invasive imaging method is difficult to apply for high resolution multi-channel scans of 
larger areas or the whole body of a mouse, in particular due to the very long scanning 
times required. Therefore, in order to assess whole body distribution and reciprocal 
localization of both probes, Cetux-Alexa-647 and hIgG-Alexa-750, following each Optix 
MX2 scan mice were also scanned with the IVIS Spectrum using the spectral unmixing 
tool. Figure 16 shows an overlay of the two fluorescent signals derived from the Cetux-
Alexa-647 and hIgG-Alexa-750 probes, detected in vivo in the AsPC-1 and MIA PaCa-2 
tumor bearing mice 24 h after co-injection of both probes. As expected, Cetux-Alexa-647 
derived fluorescence (red) was localized over the primary tumor in the MIA PaCa-2 model, 
whereas AsPC-1 mice showed Cetux-Alexa-647 derived fluorescence over both, the 
primary tumor and the surgical scar grown above it. No accumulation of Cetux-Alexa-647 
in any other organs of both animals was observed. hIgG-Alexa-750 (green) accumulated 
in the liver in both tumor mouse models. In the overlays, yellow signals over the bladder 
were frequently visible, presumably representing the renal excretion of the unbound dyes, 




Figure 16: Overlays/Spectral unmixing of Cetux-Alexa-647 and hIgG-Alexa-750 signals obtained in vivo 
by IVIS Spectrum. Representative composite images obtained by spectral unmixing of IVIS scans 24 h after 
co-injection of Cetux-Alexa-647 (red) and hIgG-Alexa-750 (green) into AsPC-1 (left) and MIA PaCa-2 (right) 
tumor bearing mice. Cetux-Alexa-647 derived fluorescence signals were determined at the tumor site and at 
the tumor mass developed at the surgical incision (S/T) in the AsPC-1 model, or at the primary tumor site (T) 
in the MIA PaCa-2 model. By contrast, the control probe localizes only at the liver (L) in both tumor mouse 
models. Note, that a yellow signal over the bladder in the MIA PaCa-2 xenograft (B; right panel) is also visible, 
representing the co-localization of both signals. 
 
In order to precisely localize the fluorescence images to the anatomical structure of the 
mice, we exemplarily performed a co-registration of 3D fluorescence data obtained by 
IVIS Spectrum with µCT scans performed with the Quantum FX using AsPC-1 tumor 
bearing mice (n=2) 24 h after the i.v. injection of Cetux-Alexa-647. The results of the co-
registration are shown in Figure 17a, and demonstrate that Cetux-Alexa-647 derived 
fluorescence (orange) is visible in the upper abdominal cavity next to the stomach and 
duodenum that are highlighted by iodine containing contrast agent used for the CT scan. 
Additional fluorescence was detected over the bladder (B) and most probably derived, 
similar as stated above, from the free dye, here from Alexa-Fluor-647. In the center 
(Figure 17b), the ex vivo image of the same mouse confirmed the location of the AsPC-1 
pancreatic tumor (T). The macroscopic image of the primary tumor in Figure 17c, confirms 
that the tumor is localized between the stomach (S) and the duodenum (D). 
Co-registration of the control probe hIgG-Alexa-750 alone with the anatomical structure of 





Figure 17: Correlation of Cetux-Alexa-647 to anatomical structures in vivo by co-registration of 3D 
fluorescence signals with µCT data. (a) Fusion of the 3D NIRF data sets with 3D µCT demonstrates 
correlation of the Cetux-Alexa-647 derived fluorescence to the site of the pancreatic tumor. The other intense 
fluorescence signal visible in the scan is derived from the bladder (B). (b) Corresponding photograph of the 
same animal ex vivo confirms that the pancreatic tumor (T, white dashed circle) developed on the left side of 
the mouse and dorsal to the liver. (c) Macroscopic appearance of the primary pancreatic tumor (T) confirms 
that it extended between the stomach (S) and the duodenum (D). 
 
Taken together, we could clearly show that Cetux-Alexa-647, but not the control hIgG-
Alexa-750 antibody, specifically accumulates in both, AsPC-1 and MIA PaCa-2, primary 
tumors in vivo, with a more pronounced accumulation in high EGFR expressing AsPC-1. 
Moreover, the AsPC-1 primary tumor was perfectly visualized by Cetux-Alexa-647 derived 
signal within the anatomical structure of the mouse.  
 
3.2.4.2 Validation of the specificity of in vivo signals by fluorescence LTs 
In order to confirm that the fluorescence signals detected in vivo over the tumor and the 
liver of the PDAC mice were specific for Cetux-Alexa-647 and hIgG-Alexa-750, 
respectively, we measured fluorescence LTs of the two conjugates in vitro (Figure 18a) 
and compared them with the fluorescence LTs of the signals measured in vivo 24 h after 
injection (Figure 18b). 
The TPSFs (Figure 18a, middle) of representative points on the in vitro scans of Cetux-
Alexa-647 (left) and hIgG-Alexa-750 (right) revealed LTs of 1.34 ns and 0.59 ns, 
respectively. Comparable fluorescence LTs were obtained for the in vivo scans (Figure 
18b; middle). Cetux-Alexa-647 scans (Figure 18b; left) showed LTs of 1.37 ± 0.05 ns at 
the tumor site in the AsPC-1 and 1.47 ± 0.02 ns in the MIA PaCa-2 mouse model, 
whereas hIgG-Alexa-750 scans (Figure 18b; right) revealed LTs of 0.73 ± 0.02 ns over the 
liver in the AsPC-1 and 0.71 ± 0.03 ns in MIA PaCa-2 mouse model, confirming that the 




Figure 18: In vitro and in vivo fluorescence LTs of Cetux-Alexa-647 and hIgG-Alexa-750. (a) 
Representative in vitro scans of both probes, Cetux-Alexa-647 (left) and hIgG-Alexa-750 (right) taken with 
Optix MX2. Middle panel shows the corresponding representative TPSFs. The monoexponential decay of 
each curve was used to calculate the fluorescence LT of both, the EGFR targeting probe Cetux-Alexa-647 
(1.34 ns) and the control probe hIgG-Alexa-750 (0.59 ns). (b) The same representative in vivo intensity scans 
of AsPC-1 (left) and MIA PaCa-2 (right) mouse models 24 h after probe injection that are also shown in Fig. 
15a, with corresponding LT maps as well as representative TPSFs (middle panel), demonstrating that in vivo 
fluorescence LTs over the tumors (for Cetux-Alexa-647) and the liver (for hIgG-Alexa-750) are comparable to 
the in vitro LTs of each probe. TPSFs are graphed as fluorescence intensity [NC] versus time [ns]. 
 
3.2.5 Cetux-Alexa-647 detects PDAC primary tumors and metastases by ex vivo 
optical imaging 
In order to confirm the exact location of the in vivo Alexa-647 and Alexa-750 signals, mice 
were sacrificed and consecutively scanned ex vivo with opened abdominal cavity using 
Optix MX2 (Figure 19) and IVIS Spectrum (data not shown) 48 h after probe injection, a 
time point when the in vivo fluorescence signal had clearly decreased. 
As shown in the left panel of Figure 19, Cetux-Alexa-647-derived signals were clearly 
localized over the MIA PaCa-2 and AsPC-1 primary tumors (white arrow, T) as well as at 
the tumor nodules on the scar of the AsPC-1 model (white arrow, S), depicted also in the 
ex vivo image of the mouse (middle panel; primary tumor = white dashed tracing; scar = 
red dashed tracing). Consistently, no hIgG-Alexa-750 derived fluorescence signals (Figure 
19, right panel) were visible over the MIA PaCa-2 or the AsPC-1 tumor area, but the hIgG-
Alexa-750 derived signals clearly were localized at the liver. NIRF scans of Cetux-Alexa-
647 and hIgG-Alexa-750 frequently revealed high fluorescence signals detected within the 




Figure 19: Ex vivo detection of Cetux-Alexa-647 over AsPC-1 and MIA PaCa-2 primary tumors. Ex vivo 
NIRF scans of Cetux-Alexa-647 (left) and hIgG-Alexa-750 (right), of the same AsPC-1 (upper panel) and MIA 
PaCa-2 tumor bearing mice (lower panel) shown in Figure 15 (in vivo scans), after opening the abdominal 
cavity. The corresponding photographs of the mice (middle panel) confirm the presence of AsPC-1 and MIA 
PaCa-2 primary tumors (white dashed tracing) and the localization of the tumor mass developed at the 
surgical scar of AsPC-1 mice (red dashed tracing). Cetux-Alexa-647 signals co-localize with the AsPC-1 and 
MIA PaCa-2 tumor areas (T = primary tumor, S = tumor mass at the surgical incision, white arrows), whereas 
hIgG-Alexa-750 signals co-localize with the liver (L). B (white arrow) indicates the fluorescence signal coming 
from the bladder of AsPC-1 and MIA PaCa-2 mice detected on both Cetux-Alexa-647 and hIgG-Alexa-750 
NIRF scans. 
 
Primary tumor, spleen, lung, liver, kidney, mesentery, lymph nodes and diaphragm from 
both PDAC mouse models that received the double injection of Cetux-Alexa-647 and 
hIgG-Alexa-750 were explanted and scanned ex vivo with Optix MX2 (Figure 20) and IVIS 
Spectrum (data not shown). As shown on the left of Figure 20a, upper panel, in addition to 
the primary tumors developed in both tumor models, also the metastatic sites of the 
AsPC-1 model at the diaphragm, left liver lobe and mesentery as well as the tumor mass 
at the site of surgical incision (arrows), displayed a strong Cetux-Alexa-647 derived 
fluorescence. Since no metastases in the peritoneal organs and over the scar were 
macroscopically found in the MIA PaCa-2 tumor bearing mouse, no fluorescence signals 
were observed over the different organs (Figure 20a, lower panel). These findings are 
consistent with the characteristic low metastatic behavior of the MIA PaCa-2 mouse tumor 
model in comparison to the high number of metastases found in the AsPC-1 model, as 
also described in section 3.2.3.1. On the contrary, representative NIRF scans for the 
control probe hIgG-Alexa-750 shown on the right of Figure 20a revealed, together with the 
corresponding photograph in the middle panel, only a strong accumulation of hIgG-Alexa-
750 within the liver of both mouse models, whereas only background fluorescence signals 
were detected over AsPC-1 and MIA PaCa-2 primary tumors (white circles). 
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Furthermore, the average ex vivo fluorescence intensities of Cetux-Alexa-647 and hIgG-
Alexa-750 over tumor areas (white circles) were quantified (Figure 20b). Ex vivo scans 
confirmed that AsPC1 tumors displayed a significantly (p=0.04) higher Cetux-Alexa-647 
average fluorescence intensity than the MIA PaCa-2 tumors. On the contrary, only very 
low hIgG-Alexa-750 average fluorescence intensities could be measured over tumor 
areas, with no significant differences when comparing the low hIgG-Alexa-750 signals 
over AsPC-1 and MIA PaCa-2 tumors. 
 
 
Figure 20: Biodistribution of Cetux-Alexa-647 analyzed by ex vivo NIRF imaging. (a) Representative ex 
vivo NIRF scans of Cetux-Alexa-647 (left) and hIgG-Alexa-750 (right) of the excised AsPC-1 (upper panel) 
and MIA PaCa-2 (lower panel) tumors and organs as well as the corresponding photograph (middle). Cetux-
Alexa-647 derived fluorescence was detected over both, AsPC-1 and MIA PaCa-2 primary tumors (white 
circles) as well as in the AsPC-1 model over metastases in the mesentery, pancreas and in the left liver lobe 
(arrows). The control hIgG-Alexa-750 was not visible over the tumor areas of both tumor models but 
accumulated clearly in the liver (right). (b) Box plots of average ex vivo fluorescence intensities [NC] of Cetux-





3.2.6 Validation of Cetux-Alexa-647 fluorescence by NIRF microscopy 
Binding of the i.v. injected Cetux-Alexa-647 to tumor cells within AsPC-1 and MIA PaCa-2 
primary tumor was confirmed by NIRF microscopy of tissue sections obtained from mice 
that received Cetux-Alexa-647 and hIgG-Alexa-750 simultaneously. Tissues were stained 
ex vivo by immunohistochemistry with anti-EGFR antibody targeting a different epitope of 
the receptor than Cetuximab. Figure 21 shows the binding of in vivo administered Cetux-
Alexa-647 (red) to tumor cells expressing EGFR (ex vivo staining, green). Cetux-Alexa-
647 (red) clearly bound only to EGFR-positive cells, stained in green. Nevertheless, some 
cells showed solely green staining, suggesting that in vivo injected Cetux-Alexa-647 
conjugate did not bind to every tumor cell that expresses EGFR. As expected, hIgG-
Alexa-750 derived fluorescence was not detected within the primary tumor sections by 
NIRF microscopy (data not shown).  
 
Figure 21: Binding of in vivo injected Cetux-Alexa-647 to tumor cells analyzed by ex vivo NIRF 
microscopy. NIRF microscopy of paraffin sections of AsPC-1 (left) and MIA PaCa-2 (right) primary tumors 
excised 48 h after i.v. injection of both, Cetux-Alexa-647 and hIgG-Alexa-750 and co-stained by IHC with an 
anti-EGFR antibody confirmed binding of the in vivo applied Cetux-Alexa-647 (red) to the membrane of 
EGFR-positive tumor cells (green), although not to all EGFR expressing tumor cells. Nuclei are counterstained 
with DAPI (in blue). Scale bars represent 50 µm.  
 
Taken together, in vivo and ex vivo analysis of Cetux-Alexa-647 distribution by NIRF 
imaging, demonstrate the suitability of the NIRF Cetuximab conjugate to visualize not only 
primary PDAC tumors but also various metastases in multiple peritoneal organs, 
especially in the highly aggressive AsPC-1 model. NIRF microscopy confirmed specific 
binding of Cetux-Alexa-647 to EGFR expressing tumor cells, however not to all EGFR 
positive cells. Therefore, application of Cetux-Alexa-647 for fluorescence-guided 




3.2.7 Cetux-800CW detects AsPC-1 tumors and metastases during fluorescence-
guided dissection 
In order to evaluate Cetuximab as a tool for fluorescence-guided surgery, Cetuximab was 
conjugated to the IRDye 800CW (Cetux-800CW) to adapt the fluorophore to the settings 
of the Quest Spectrum clinical device for FGS. Cetux-800CW (25 ug) was employed i.v. 
during fluorescence-guided dissection of AsPC-1 tumor bearing mice (n=5), 30 days after 
tumor cell transplantation. 24 h after the injection of the probe, tumor bearing mice were 
sacrificed to proceed with the dissection accompanied by real time monitoring with the 
Quest Spectrum clinical system for FGS. 
Figure 22a shows selected frames of the representative real-time movie made during the 
progressive steps of the dissection, showing overlays of the two views of the camera. The 
first two frames show the mouse with intact skin (Frame 1) and peritoneum with scans of 
three highly fluorescent areas over the upper abdomen (Frame 2), immediately taken after 
sacrifice and exposure to the camera. The larger fluorescent area represents the tumor 
mass that developed at the surgical scar (S), whereas the two small fluorescent lesions 
(M1 and M2) may correlate to metastatic sites. Frame 3 shows clear delineation of the 
primary tumor mass (T) that show high fluorescence signals, partially covered by the liver. 
Furthermore, the tumor mass developed at the site of surgical incision (S), after opening 
the peritoneum of the mouse is clearly visible. In addition, tumor lesions, such as M1 (at 
the peritoneum, close to the larger tumor mass developed at the surgical incision) and M2 
(at the costal arch) shown in the previous frame could be clearly localized and a small 
metastasis at the left liver lobe (M3) was further detected at this stage. Frame 4 shows the 
entire primary tumor (T) that was then exposed to the camera enabling its image-guided 
resection. Furthermore, multiple tumor nodules (M4), hardly discernable with the naked 
eye, were detected along the stomach. The ex vivo image of the same mouse (Figure 
22b) shows the macroscopic appearance of the tumor (T, black arrow), the tumor mass at 
the surgical incision (S, black arrow) and the very small metastases at the costal arch 








Figure 22: Cetux-800CW detects AsPC-1 primary tumor, the tumor mass at the surgical incision and 
metastases during fluorescence-guided dissection. (a) Representative movie-frames (Frame 1-4) 
recorded with the Quest Spectrum imaging system during fluorescence-guided dissection of a AsPC-1 tumor 
bearing mouse (n=5) 24 h after injection of 25 μg of Cetux-800CW, showing accumulation of the probe 
(green) within the primary tumor (T), at the tumor mass at the surgical incision (S), and within small 
metastases (M1-4). (b) Corresponding photograph of the same mouse with opened abdomen, showing 
macroscopic appearance of the primary tumor, of the tumor mass developed at the surgical incision and of the 
tumor lesion at the costal arch which is barely visible without fluorescence guidance. 
 
 
In order to compare the distribution of Cetux-800CW to Cetux-Alexa-647 and exclude any 
interference of the dye in the localization of the probe, mice that received Cetux-800CW 
were analyzed by Optix MX2 in vivo before the fluorescence-guided dissection and ex 
vivo after fluorescence-guided dissection by imaging the excised organs, as previously 
performed with the mice that had received Cetux-Alexa-647. Figure 23a shows the in vivo 
Optix MX2 scan of the same mouse analyzed in Figure 22. Cetux-800CW derived 
fluorescence in vivo was specifically localized over the AsPC-1 tumor. Moreover, ex vivo 
scans confirmed the specificity of the fluorescence signal over primary tumor, the 
metastases, i.e. in the liver (arrow), and the infiltrated tumor mass at the surgical incision 
(scar; arrow) which was earlier detected during fluorescence-guided dissection (Figure 
23b). The metastasis at the costal arch detected by fluorescence-guided dissection did 
not reveal any fluorescence signal by Optix MX2 scans. Fluorescence signal was also 
present over a retroperitoneal metastasis (not shown in Figure 22, but also detected 
during fluorescence-guided dissection), as well as infiltrating cells into the pancreas 
(arrow). A moderate fluorescence signal was also depicted over the whole healthy liver, 





Figure 23: Cetux-800CW fluorescence signal detected over AsPC-1 primary tumor and metastases by 
in vivo and ex vivo NIRF imaging. The same AspC-1 bearing mouse undergoing fluorescence-guided 
section and presented in Figure 22 was scanned for NIRF imaging by Optix MX2. (a) Representative images 
of the in vivo prescan (the day before the fluorescence-guided surgery) and 24 h scan (just before the start of 
fluorescence-guided surgery) after Cetux-800CW injection reveal an accumulation of the probe specifically at 
the tumor site. (b) Representative images of ex vivo NIRF imaging obtained by Optix MX2 of extracted organs 
of the same mouse that was scanned in vivo by Optix MX2 and subsequently underwent fluorescence-guided 
dissection (Figure 22). Cetux-800CW derived signals were detected over the primary tumor, at the tumor 
mass developed at the surgical incision (scar), but also over small metastases located at the liver and in the 
retroperitoneum (white arrow). Cells infiltrating the stomach (asterisk) were also detected. The small 
metastasis at the costal arch did not show any fluorescence signal (white arrow). A low fluorescence signal 
was detected over the rest of the liver. 
 
3.2.8 Ex vivo validation of Cetux-800CW fluorescence signals of tumor and 
metastases 
As fluorophores emitting fluorescence in the range of 800 nm cannot be analyzed by our 
NIRF microscopes, Cetux-800CW derived fluorescence was further assessed on sections 
of AsPC-1 primary tumors and of metastatic sites using the Odyssey scanner. Figure 24a 
revealed that only the vital part of the primary tumor was stained with the i.v. injected 
Cetux-800CW (green), whereas the necrotic part in the tumor center, confirmed by HE 
staining (right panel; N) did not show any Cetux-800CW-derived fluorescence. Moreover, 
tumor cells that bound Cetux-800CW and invading the stomach (S) and the duodenum 
(D) were also clearly visualized by Odyssey (white arrow). Cetux-800CW-derived 
fluorescence was also found specifically at the tumor mass developed at the scar (Figure 
24b), and at the two small (~1 mm) metastases present in the liver lobe (Figure 24c) as 
well as at the costal arch (Figure 24d), all sites that were previously detected by Quest 




Figure 24: Confirmation of Cetux-800CW fluorescence signals at primary tumor and metastases by 
Odyssey system. (a) Odyssey scan of a representative primary AsPC-1 tumor (T) embedded together with 
adjacent stomach (S) and duodenum (D) (left) and corresponding HE staining (right). Cetux-800CW derived 
fluorescence (green) is observed at the vital part of the primary tumor and at the site of tumor invasion (arrow) 
into the stomach (S) and duodenum (D), but not at the necrotic area (N). (b-d) Odyssey scans and 
corresponding HE staining of tissue sections confirming the presence of Cetux-800CW derived fluorescence 
(b) at the tumor mass that developed at the surgical incision and at two small metastases (~1 mm) developed 
(c) at the liver and (d) at the costal arch. All the metastatic lesions were previously detected by fluorescence-
guided surgery as shown in Figure 22. 
 
Taken together, Cetuximab conjugated with NIRF dyes is a valuable tool to visualize not 
only the primary tumor but also very small metastatic lesions by NIRF imaging and by 
FGS. 
 
3.3 Proof-of-Concept: Validation of treatment efficacy targeting EGFR in 
combination with NHE1 in the orthotopic AsPC-1 tumor mouse model 
Next, the AsPC-1 tumor mouse model was applied to validate the efficacy of a novel 
therapeutic strategy, the combination of Erlotinib and Cariporide, on tumor growth, 
invasion and metastatic spread in vivo. Erlotinib is a target of EGFR, while Cariporide is a 
specific inhibitor of the activity of NHE1, a sodium/hydrogen exchanger, known to be 
implicated in the maintenance of the acidic tumoral pH. For this study the AsPC-1 tumor 
model was chosen which is characterized by the high aggressive tumor phenotype with 
invasion and metastatic spread. Earlier in vitro results had also demonstrated that 
inhibition of both, EGFR and NHE1 activity, by Erlotinib and Cariporide, respectively, 
reduced the formation of invadopodia in AsPC-1 cells (unpublished data, personal 
communication of Prof. Reshkin and colleagues, from University of Bari, Italy). 
 
3.3.1 Treatment schedule of Erlotinib/Cariporide therapy in AsPC1 tumor bearing 
mice 
To validate the efficacy of the combined Erlotinib/Cariporide therapy on tumor 
progression, treatment was started 10 days after transplantation. This time was chosen 
since at this time point we found that the primary AsPC-1 tumors presented an average 
volume of 7.9 ± 0.1 mm3 (n=4), but no macroscopical appearance of invasion or 
metastatic spread into peritoneal organs as yet. Mice transplanted with tumor cells 10 
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days prior to the start of the experiment were randomly divided into four groups and 
treated following the therapeutic schedule shown in Figure 25: for 20 days they received 
daily either Erlotinib (50 mg/kg of body weight (BW) in Captisol 6%, orally, n=7) or 
Cariporide (3 mg/kg of body weight (BW) in NaCl 0.9%, i.p. n=7) or a combination of both 
(n=7) or the corresponding vehicles as controls (NaCl 0.9% i.p. and Captisol 6% orally; 
n=6).  
All mice were sacrificed at day 30 after AsPC-1 cell transplantation, since at this time point 
untreated AsPC-1 mice usually developed an average primary tumor mass of 171 ± 118 




Figure 25: Time schedule and therapy groups of the Erlotinib/Cariporide therapy. 
 
3.3.2 Tolerance of the treatment and effect on body weight of the mice 
All treatment regimes were well tolerated by all mice. At the day of sacrifice, body weights 
of the animals were recorded and scored. As shown in Figure 26, the highest loss of body 
weight of ΔWM = -4.7% ± 4.2% was observed in the group treated with Erlotinib alone. A 
minor loss in body weight was seen also in the control group (ΔWM = -1.8% ± 10.5%) and 
in the Erlotinib/Cariporide- double treated group (ΔWM = -1.2% ± 13.1%), although both 
groups showed relatively high standard deviations. Interestingly, the group treated with 




Figure 26: Effect of the combined Erlotinib/Cariporide therapy on body weight. The weight at the end of 
the therapy was calculated for all treatment groups as a percentage of the initial body weight. Red line marks 
100% corresponding to unchanged weight. Mice of the control and the Erlotinib/Cariporide groups show 
similar average body weight measured before the dissection. In comparison to the control group, mice treated 
with only Cariporide show higher average body weights whereas Erlotinib-treated mice show a decrease in 
the body weight. 
 
3.3.3 Effect of Erlotinib/Cariporide therapy on primary tumor growth 
The influence of the different treatments on tumor growth was assessed by manually 
measuring primary tumor volumes with a caliper during section (Figure 27). No significant 
inhibitory effect on the tumor growth was observed in response to therapy, neither to 
Cariporide nor to Erlotinib given alone, nor to the combination of both drugs. However, 
mice treated with Cariporide alone developed a larger primary tumor (140 ± 16 mm3) in 
comparison to the controls with an average primary tumor volume of 95 ± 27 mm3. The 
highest variation in tumor volumes were found in the Erlotinib-treated group with an 
average tumor volume of 109 ± 34 mm3 and tumor sizes that were comparable to those of 
controls. A slightly reduced primary tumor volume in comparison to the control group was 
found only for tumors that were treated with combined Cariporide/Erlotinib (80 ± 15 mm3), 




Figure 27: Effect of Erlotinib/Cariporide therapy on primary tumor growth. Primary tumor volumes (mm3) 
of the mice of the different groups, measured with caliper during the dissection. In comparison to the control 
group (95 ± 27 mm3), Cariporide-treated mice show a higher average tumor volume (140 ± 16 mm3) whereas 
Erlotinib-treated mice show a slight increase in the average tumor volume, but with high variability (109 ± 34 
mm3). A slight decrease in the average tumor volume in comparison to the control group was seen in the 
Erlotinib/Cariporide-double treated group (80 ± 15 mm3). 
 
3.3.4 Effect of Erlotinib/Cariporide therapy on tumor infiltration into the stomach 
and duodenum 
To evaluate the grade of invasion of tumor cells into adjacent organs such as stomach 
and duodenum in response to therapy in the AsPC-1 tumor mouse model, we stained the 
tumor cells in paraffin tumor sections immunohistochemically with anti-EGFR antibody. 
Tissue sections were taken from 4 different plains of the tumor mass embedded in paraffin 
blocks together with the adjacent organs such as stomach and part of the duodenum. As 
shown in the images of the histological sections in the upper panel of Figure 28 (upper 
part), EGFR staining identifies even small groups of tumor cells infiltrating the mucosa of 
the stomach and duodenum. The grade of invasion was scored according to the extent of 
tumor cells infiltrating the different layers (serosa, muscularis, mucosa) of duodenum and 
stomach, stained by anti-EGFR antibody (- = no infiltration; L = low infiltration, single 
tumor cells start to invade the serosa; M = medium infiltration, tumor cells invade the 
serosa and muscularis; H = high infiltration, tumor cells invade the mucosa). 
As shown in Figure 28 (lower part), mice of the untreated control group showed a high 
infiltration grade into the stomach (5/6 mice) whereas most of the mice showed no tumor 
cell infiltration into the duodenum (4/5 mice). Treatment with Cariporide only resulted in 
primary tumors that showed infiltration into the stomach at different grades (2/7 mice with 
low, 3/7 mice with medium and 2/7 mice with high infiltration). The majority of Erlotinib-
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treated mice revealed primary tumors with a medium (4/7 mice) and high (2/7 mice) grade 
of infiltration into the stomach. In both Cariporide and Erlotinib-only treated groups, high 
infiltration in the duodenum was observed (4/6 mice and 4/7 mice, respectively). Instead, 
tumor tissue sections from combined Erlotinib/Cariporide-double treated mice showed that 
only two mice had high infiltration of tumor cells into the stomach, one had only low 
infiltration, whereas 3/7 mice revealed no infiltration at all. The grade of tumor infiltration in 
the duodenum of the double treated mice (5/7 mice with no infiltration, 2/7 mice with high 
infiltration) was found to be similar to the control group. 
 
* analysis of duodenum infiltration was not possible in one animal. 
Figure 28: Analysis of the invasion grade of AsPC-1 tumor cells into the stomach and duodenum 
evaluated by EGFR staining. Squares depicted in the images show different amount of infiltration which was 
relatively quantified by scores. (0 = no infiltration; L = low infiltration, single tumor cells starts to invade the 
serosa; M = medium infiltration, tumor cells invade the serosa and muscularis; H = high infiltration, tumor cells 
invade the mucosa). Serosa (Se), muscularis (Mus) and mucosa (Muc) layers are exemplarily shown in the 
figure with low infiltration (L). 4 different slides of the primary tumor were evaluated for each model and the 
highest score was taken into account. Minor invasion of tumor cells into the stomach was only found in the 
Erlotinib/Cariporide treated group in comparison to the control group, whereas the invasion of the duodenum 
of the Erlotinib/Cariporide double treated mice was not affected. No effect was seen on the invasion of tumor 
cells in the stomach and duodenum in response to administration of either Cariporide alone or Erlotinib alone. 
 
In conclusion, only the Erlotinib/Cariporide-double treated group revealed a minor effect 
on the invasion behavior by showing a reduced degree of infiltration into the stomach, 





3.3.5 Effect of Erlotinib/Cariporide therapy on metastatic spread 
To evaluate the effect of Erlotinib and Cariporide alone or in combination on the 
metastatic load, peritoneal organs such as liver, spleen, kidney and diaphragm were 
macroscopically analyzed in all mice for the presence and number of metastases. The 
presence of tumor mass at the surgical incision was also recorded. 
The results of the metastatic tumor spread in the different treatment groups are 
summarized in Table 8. In the control group, most of the mice presented metastatic 
lesions in the liver (3/6 mice), kidneys (3/6 mice), spleen (3/6 mice) and diaphragm (4/6 
mice). The groups receiving the therapy with either Cariporide or Erlotinib showed equal 
numbers of mice with metastatic findings comparable to controls. For example, the 
Cariporide-treated group metastasized to the liver (4/7 mice), kidneys (4/7 mice) and 
spleen (4/7 mice). Only a minor reduction in the incidence of metastases was observed in 
the diaphragm (2/7 mice) of the Cariporide-treated mice in comparison to controls. In 
Erlotinib-treated mice, metastases were observed in the liver and diaphragm (4/7 mice), 
whereas less mice (2/7 mice) were observed with metastases in the spleen in comparison 
to the controls; kidneys were completely free of metastases. Cariporide and Erlotinib 
alone had no effect on the development of a tumor mass at the surgical incision site (4/7 
mice) in comparison to the controls. 
By contrast, Erlotinib/Cariporide-double treated mice showed a reduced metastatic spread 
with no metastases findings in the kidney and with a low number of metastases located in 
the liver (1/7 mice), and diaphragm (2/7 mice), when compared to the control group. The 
number of double treated mice with spleen metastases (3/7 mice) was comparable to the 
controls. Moreover, double treated mice did not develop as often a tumor mass at the 














Table 7: Effects of Erlotinib/Cariporide therapy on metastatic spread in AsPC-1 tumor bearing mice. 
Liver, kidney, spleen and diaphragm were analyzed for the presence of macroscopic metastases, together 
with infiltration of tumor cells at the site of surgical incision. The control group presents a high incidence of 
metastases (50-66%) in all considered organs as well as infiltration at the site of surgical incision. 
Erlotinib/Cariporide-double treatment showed a slight inhibitory effect on the metastatic spread to kidneys, 
liver and diaphragm and a slightly reduced number of mice with infiltration at the site of surgical incision.  
 
The metastatic load in the mesentery was also evaluated in response to therapy in all 
groups (Figure 29). A high number of metastases with sizes of 1, 2 and 3 mm was 
observed in the control group in comparison to all treated groups. A strong reduction in 
mesenterial metastases was found in the Erlotinib/Cariporide-double treated group for all 
sizes of metastases, whereas a reduced number of metastases was found in both 
Cariporide- and Erlotinib-only treated mice, especially for metastases of sizes of 2 mm 
and 3 mm. 
Cariporide and Erlotinib alone had no effect on the metastatic behavior of the tumor cells 
in the AsPC-1 model. However, Erlotinib/Cariporide applied together showed a minor 
inhibition of metastatic spread to the liver, kidneys and mesentery, and also reduced 
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Figure 29: Effects of Erlotinib and Cariporide on the metastatic load in mesentery. During section, the 
mesentery of the animals was exposed and the number of macroscopic metastases was counted. A high 
decrease of metastases of different sizes (1mm, 2mm and 3mm) were observed in the Erlotinib/Cariporide-
double treated mice in comparison to the controls. A minor reduction in number of metastases, especially of 2 
mm and 3 mm, was found in the Cariporide- and Erlotinib- only treated groups. 
 
Taken together, Erlotinib/Cariporide-double therapy did not affect the growth of the 
primary tumor, but showed some efficacy on steps of tumor progression such as reducing 
the invasion behavior of the tumor cells into the stomach and at the surgical incision, and 
inhibiting the metastatic spread to organs such as liver, kidney and mesentery. 




4.1 Orthotopic human PDAC mouse models with distinct growth and metastatic 
behavior 
In the first part of my study, five orthotopic mouse models of human PDAC, each derived 
from different human pancreatic tumor cell lines were successfully established. 
At the time when symptoms suggested PDAC growth (defined by us as time of 
development), all orthotopic PDAC mouse models developed PDAC tumors presenting 
macroscopic invasion into the stomach and duodenum, which is a characteristic tumor 
growth behavior also seen during the progression of PDAC in humans. PDAC tumors 
developed at different time points after cell transplantation, with tumor take rates between 
75% and 100% depending on the transplanted cells, with strong differences in tumor size. 
MIA PaCa-2 and Capan-1 transplanted mice developed tumors after ~90 and ~120 days 
respectively, with much larger tumor masses in comparison to the other three PDAC 
models, and varying highly in tumor sizes (845 ± 428 mm3 and 1183 ± 812 mm3) in 
comparison to the other three. In fact, BxPC-3 and PANC-1 transplanted mice developed 
smaller tumor masses (193 ± 111 and 294 ± 194 mm3) after ~90 and ~115 days, 
respectively, whereas the AsPC-1 model was the only one among the five tested, that 
developed tumors of 122 ± 93 mm3 in size in a very short period of 30 days after cells 
transplantation. Moreover, the AsPC-1 model, with a tumor take rate of 100%, showed an 
aggressive phenotype with high metastatic spread in various peritoneal organs in 
agreement with previous studies reporting AsPC-1 as a highly aggressive cell line in vivo 
[88, 89]. In contrast, we showed that the MIA PaCa-2 model revealed almost no peritoneal 
metastatic spread, however with common invasion of tumor cells into the liver hilus, 
occasionally resulting in jaundice. These findings demonstrate that AsPC-1 and MIA 
PaCa-2, resemble a metastatic tumor spread typical of PDAC but with two different 
characteristic grades of dissemination, one with a high metastatic (AsPC-1) phenotype 
and one with a low metastatic (MIA PaCa-2) phenotype. Altogether, these results indicate 
that there is no linear correlation between the tumor size, the grade of differentiation, and 
the aggressiveness of the models, but all strongly depend on the intrinsic characteristic of 
the transplanted cells. It is of interest to observe that only the AsPC-1 mouse model, 
which is the only one derived from the ascites of a PDAC patient, shows a high 
aggressive phenotype with a very short time of development and metastatic spread. This 
also suggests that the metastatic spread is not due to a possible microscopical cell 
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leakage during operation as reported by others [90], which may overestimate the number 
of metastatic findings in mice in comparison to the human disease.  
Moreover, histological analysis revealed that each orthotopic PDAC mouse model 
established here reflected characteristic morphological and pathological features, such as 
desmoplastic reaction, a hallmark of human pancreatic cancer. AsPC-1, MIA PaCa-2 and 
PANC-1 xenografts presented a poorly undifferentiated morphology with completely 
unorganized tumor cells, although the transplanted cells derived from different origins, 
ascites of a PDAC patient (AsPC-1) and from a PDAC tumor of a patient with signs of 
metastases (MIA PaCa-2 and PANC-1). By contrast, BxPC-3 and Capan-1 differentiated 
tumors are both characterized by tumor cells organized in clusters. Especially Capan-1 
tumors, which were derived from a liver metastasis of a PDAC patient, closely resemble 
the duct-like morphology typical for human PDAC. Our histological findings of the grade of 
differentiation of the tumors were already described by others, that applied the PDAC 
mouse models for preclinical imaging or therapeutic studies mainly using Capan-1 [91], 
BxPC-3 [92], AsPC-1 [93], MIA PaCa-2 and PANC-1 [94] mouse models. However, the 
majority of the researchers used subcutaneous tumor models, which usually show faster 
tumor growth rates and no invasion and metastatic spread [95].  
Similar amounts of PSCs were present in all primary PDAC tumors with comparable 
myofibroblastic-like morphology. Instead, a high amount of deposition of elongated 
collagen fibers, resembling the fibrotic reaction typical of human PDAC, was only found in 
the Capan-1 model, whereas all others developed a fibrotic reaction as well, however to a 
minor degree. PSCs and collagen fibers were located around the duct-like- or round 
clusters of the differentiated Capan-1 and BxPC-3 tumors, respectively, whereas the 
poorly differentiated models (AsPC-1, MIA PaCa-2 and Panc-1) revealed the presence of 
disperse and unorganized PSCs, together with elongated collagen fibers, all over the 
tumor among the cells. The presence of PSCs and collagen in PDAC mouse models such 
as Capan-1 [96], MIA PaCa-2 and PANC-1 [94] has been described by positive staining of 
α-SMA and/or collagen before but only on subcutaneous PDAC tumors. Similar to these 
previous results, we found strong staining with α-SMA and Sirius Red in the same peri-
tumoral regions, confirming that mouse PSCs are the major producers of collagen not only 
in human PDAC [11] but also in PDAC xenografts. Moreover, the finding of elongated 
collagen fibers found here in all PDAC models is in agreement with previous observations 
that collagen fibers, which are typically curly and anisotropic in normal tissue, 
progressively thicken and linearize following tumor initiation [97]. Since it has been 
already proven that fibrotic reaction impedes the diffusion of intravenously injected 
molecules throughout the tumor tissue [98], collagen deposition and presence of PSCs 
Summary and Conclusion 
69 
have to be carefully analyzed before choosing the PDAC mouse model for preclinical 
imaging or therapeutic evaluation. 
Therefore, it is clear that orthotopic mouse models derived from a single cell line do not 
represent the complexity of clinicopathological properties seen in practice in human 
disease, but each model can exploit a specific pathological characteristic of the disease. 
In fact, only scarce data are present in the literature for the characterization and 
comparison of tumor mass progression and timing of development of the different PDAC 
mouse models [24, 25]. A comparison of these studies with the data obtained here is very 
difficult, due to the different amount of tumor cells transplanted and to the different 
transplantation sites performed by others. For example, here, transplantation of 1x106 
cells into the more proximal (head) part of the pancreas was performed, obtaining in all 
models a structured tumor mass in an adequate period of time. By comparison, Hotz and 
colleagues transplanted a much higher number of AsPC-1, Capan-1 and MIA PaCa-2 
tumor cells (1x107) into the tail of the pancreas [24]. Instead, Loukopoulos and colleagues 
[25], transplanted orthotopically the same quantity of Capan-1, Panc-1, AsPC-1 and 
BxPC-3 cells as in this study, but they did not report any data for the timing of 
development and tumor volumes. Both studies showed peritoneal dissemination and 
metastases to liver, lungs and lymph nodes, each PDAC tumor model to a different extent, 
as was observed in the present study using AsPC-1 and MIA PaCa-2 mouse models. 
Along with the orthotopic or subcutaneous transplantation of cells, another established 
technique for developing orthotopic PDAC mouse models is the transplantation of small 
tumor fragments (called tumor grafts) derived from biopsies of human patients or from 
subcutaneous tumors in animals. Different groups demonstrated that mice undergoing this 
procedure developed primary tumors with characteristic features similar to those of the 
donor [20, 21]. However, the heterogeneity of cells presented in surgical biopsies (i.e. 
tumor- , stromal- , inflammatory- cells), together with the development of necrotic areas of 
different extent, makes this approach highly variable and therefore not the best choice for 
diagnostic and therapeutic ends. 
Overall, PDAC orthotopic bearing mice constitute a powerful preclinical platform, which 
has been already used in a number of studies on PDAC, for evaluating novel probes for 
imaging [93, 99, 100], for testing the effect of new treatment protocols [101] as well as for 
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4.2 NIRF labeled Cetuximab as a tool for fluorescence-guided surgery 
The results obtained in the second part of my study are the first to show the potential of 
the FDA approved therapeutic antibody Cetuximab targeting the human EGFR, labeled 
with NIRF dyes, to detect pancreatic tumors and metastatic nodules in PDAC xenografts 
in mice in combination with non-invasive in vivo and ex vivo NIRF imaging and 
fluorescence-guided dissection. 
 
4.2.1 Visualization of PDAC primary tumors and metastases with Cetux-Alexa-647 
by NIRF imaging 
By using 2D NIRF imaging in PDAC mouse models that develop tumors with different 
EGFR expression, AsPC-1 (high and homogenous EGFR expression) and MIA PaCa-2 
(high/low and heterogeneous expression), we demonstrated that Cetux-Alexa-647 
accumulates solely at the AsPC-1 and MIA PaCa-2 primary tumor sites whereas the 
control human hIgG-Alexa-750 localized only in the liver, with a maximum fluorescence for 
both antibodies observed 24 h after probe injection. This is in line with results of a 
previous study performed by our group using radiolabeled Cetuximab in combination with 
SPECT, that showed that the best time point to visualize the antibody in vivo is 24 h after 
i.v. probe injection, giving the antibody sufficient time to accumulate at the tumor site 
[103]. 
The specificity of Cetux-Alexa-647 and hIgG-Alexa-750 derived fluorescence detected in 
vivo was confirmed by comparing their fluorescence LTs in vivo at 24 h with the LTs of the 
probes dissolved in medium. Slightly higher LT values of Cetux-Alexa-647 and hIgG-
Alexa-750 derived fluorescence were measured in vivo over the tumor area which is in 
agreement with our previous observations, showing that the LT of fluorescently labeled 
antibodies, e.g. antibody targeting matriptase, can be slightly influenced by in vivo 
conditions, such as the presence of serum proteins in the blood [93]. 
By an in vivo multimodality approach using fluorescence tomography data co-registered 
with µCT, the shape and the exact 3D location of the fluorescent AsPC-1 pancreatic tumor 
targeted by Cetux-Alexa-647 was perfectly identified in relation to the gastrointestinal 
tract. This indirect approach is of high importance especially for studies involving PDAC 
models, since pancreatic tumors are not visible by palpation or by inspecting just the outer 
appearance of the mouse. A similar multiplex approach was used by our group to 
visualize PDAC xenografts [93] using 2D in vivo NIRF images of a fluorescently labeled 
anti-matriptase antibody co-registered with 3D-CT data. The 3D visualization of PDAC 
was also obtained by Hudson and colleagues [104] using a fluorescently labeled EGF in 
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combination with multispectral optoacustic tomography (MSOT), with the main limitation 
that optoacustic technology does not have a sufficient field of view (FOV) to accommodate 
the reconstruction of the entire size of a mouse. 
Ex vivo NIRF imaging of the opened abdominal cavity of AsPC-1 and MIA PaCa-2 
transplanted mice and of the explanted organs of the mice confirmed that in vivo applied 
Cetux-Alexa-647, but not the hIgG-Alexa-750, specifically accumulates at AsPC-1 and 
MIA PaCa-2 primary tumors. Furthermore, in the highly metastatic AsPC-1 model, Cetux-
Alexa-647 is able to detect metastatic lesions as small as 1 mm, whereas in the low 
metastatic MIA PaCa-2 tumor bearing mice, usually no additional accumulation of the 
Cetux-Alexa-647 was observed than at the primary tumor. 
Quantification of the ex vivo average fluorescence intensities over the primary tumors, 
showed that uptake of Cetux-Alexa-647 by high EGFR-expressing AsPC-1 primary tumors 
was significantly higher than the moderate EGFR-expressing MIA PaCa-2 primary tumors, 
whereas negligible hIgG-Alexa-750 derived control signals were measured over both, 
AsPC-1 and MIA PaCa-2 primary tumors. The moderate fluorescence signals measured 
over the MIA PaCa-2 primary tumors reflect the heterogeneous expression of EGFR 
observed throughout the MIA PaCa-2 primary tumor sections. Low expression of EGFR 
was observed in different areas within the tumor mass, whereas tumor cells in the vicinity 
or already invading stomach and duodenum showed upregulation of EGFR, in accordance 
with previous data showing that EGFR promotes metastases of human pancreatic cancer 
[48]. By contrast, a homogenous high EGFR expression was seen in the AsPC-1 tumor. 
By NIR fluorescence microscopy of tumor tissue sections from mice co-injected with 
Cetux-Alexa-647 and hIgG-Alexa-750, we showed that in both tumor models, AsPC-1 and 
MIA PaCa-2, not all EGFR-expressing tumor cells bound detectable levels of the 
intravenously injected Cetux-Alexa-647. This might be due to the poor vascularization of 
the pancreatic tumor, which may simply prevent the sufficient transport of Cetuximab to all 
tumor cells. Moreover, the high affinity of Cetuximab, together with its large size of 150 
kDa may also influence its extravasation and diffusion into the less-vascularized regions 
[105]. Nevertheless, the inhomogeneous binding of Cetux-Alexa-647 within the tumor 
does not seem to have a significant impact on the detection capacity of tumor lesions by 
in vivo or ex vivo NIRF imaging. Visualization of PDAC by targeting EGFR has not yet 
been performed, but different groups were already able to visualize PDAC in combination 
with in vivo and ex vivo NIRF by targeting highly expressed cell receptors on PDAC such 
as carbohydrate antigen 19.9 (CA 19.9) [106], mucin-1 (MUC-1) [107] and matriptase [93]. 
Another interesting approach detected Capan-2 xenografts using pH sensitive probes 
[99]. However, an essential limitation of all these studies is that the preclinical probes 
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employed will be difficult to translate into the clinic due to the possible toxicity of the 
preclinical dyes used (i.e. Alexa Fluor Dyes). 
 
4.2.2 Identification of AsPC-1 primary tumor and metastatic sites with Cetux-800CW 
by fluorescence-guided dissection 
Visualization of primary tumor and identification of multiple metastatic nodules as small as 
1 mm was realized by using Cetux-800CW during ex vivo fluorescence-guided dissection 
of high EGFR-expressing and metastatic AsPC-1 xenografts. High Cetux-800CW signals 
over the tumor area were detected even through the intact skin of the mice despite the 
inhomogeneous lighting conditions of the open camera, known to cause a lower detection 
efficacy compared to the preclinical systems [108]. Optix MX2 scans of the same mice, 
injected with Cetux-800CW and undergoing fluorescence-guided dissection, confirmed the 
localization of Cetux-800CW in vivo and ex vivo at the AsPC-1 primary tumor and 
metastatic sites. Of note, a low Cetux-800CW ex vivo signal was depicted over the 
healthy liver, which was absent in the Cetux-Alexa-647 scans. This can be explained by 
the superior tissue penetration of the long-wavelength light (~800 nm) to the shorter 
wavelength light (~647 nm) used to excite the fluorescence probes. However, it is clear 
that the hepatic signal did not interfere with the detection of Cetux-800CW at the primary 
tumor and metastases, neither by NIRF imaging nor during fluorescence-guided 
dissection. 
Odyssey scans confirmed the specificity of Cetux-800CW that binds exclusively to the 
tumor cells but does not accumulate within the necrotic areas of the tumors, as also 
recently described for clinical samples [109]. The presence of necrosis in the tumor does 
not impede the visualization of the surgical margins, since the vital tumor cells targeted by 
the fluorescently labeled Cetuximab are mainly located at the periphery of the tumor. 
Until now, there has only been a single preclinical study describing the application of the 
Quest Spectrum clinical system for the detection of preclinical tongue tumors and of 
sentinel lymph nodes in mice [110]. The same report also showed results of a clinical trial, 
using Quest Spectrum for the detection of human colorectal liver metastases that were 
located near or at the liver surface, 24h after injection of ICG. Two other FDA-approved 
intraoperative fluorescence imaging systems, SPY and FLARE, were used in preclinical 
studies in combination with different therapeutic monoclonal antibodies labeled with 
IRDye-800CW, e.g for the surgical resection of breast cancer [111], HNSCC [112], and for 
the visualization of pancreatic xenografts using a CEA-targeting single-chain antibody 
fragment [113]. Moreover, a laparoscopic preclinical approach of pancreatic surgery, 
which was performed by Bouvet and colleagues [114, 115], involved anti-CEA antibody 
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labeled with Alexa Fluor 488 dye. Although this approach seemed to be promising, 
similarly in this case the clinical translation will be difficult due to the possible toxicity of 
preclinical Alexa Fluor dyes and because the antibodies used were not FDA-approved. 
The choice to use the FDA approved Cetuximab antibody and the IRDye-800CW, which is 
currently in the process for clinical translation, was therefore reasoned as this 
fluorescence conjugate may have the best prospect for clinical approval, which requires 
that each component of the probe on trial must be verified individually for its toxicity. The 
likelihood of approval thus falls the more multi-componential the probe is. 
 
4.3 Anti metastatic effect of NHE1 and EGFR inhibition in PDAC xenografts 
In the third part of my study, AsPC-1 xenografts, characterized by a fast development of a 
poorly differentiated primary tumor that invades into the surrounding organs and 
metastasizes to multiple sites in the abdomen, were employed to evaluate the efficacy of 
a combined anti-EGFR/anti-NHE1 therapy involving Erlotinib (50 mg/kg) and Cariporide (3 
mg/kg). The major and most relevant effect of the combined Erlotinib/Cariporide- therapy 
was found in the inhibition of the metastatic spread to different peritoneal organs, 
especially to liver, kidney, diaphragm, mesentery and in the tumor infiltration at the site of 
surgical incision. Moreover, the combined therapy was able to reduce the tumor infiltration 
in the stomach of the mice. By contrast, both, Erlotinib and Cariporide administered as 
individual treatments, only had a very low effect on the metastatic spread to the kidney 
and to the diaphragm, respectively. 
The major challenge for the analysis of the effect of the therapy on the metastatic spread 
was the quantification of the effect of the different drugs. This was due to the fact that 
most of the organs analyzed displayed a number of metastases in the range of 1-4 and of 
different sizes (1-3 mm) making the comparison of the different groups difficult. The 
decision to categorize the mice either as negative or as positive for the presence of 
macroscopic metastases in the analyzed organ, independently of their number and sizes, 
allowed us though to visualize the clear difference between the groups. Moreover, by 
counting the number of metastases of different sizes (1mm, 2mm and 3 mm), we could 
clearly show the inhibitory effects of the combined treatment on the mesenterial tumor 
spread. 
Another slight (though not significant) effect of Erlotinib/Cariporide- double therapy was 
seen in the reduction of the tumor mass (average tumor mass 80 ± 15 mm3) in 
comparison to control mice (average tumor mass 95 ± 27 mm3), whereas the separate 
treatments had very different effects, from even an increase of the average tumor mass 
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(average tumor mass 140 ± 16 mm3) seen in Cariporide-treated mice, to a highly variable 
effect seen for the Erlotinib-treated mice, characterized by tumor masses ranging between 
60 and 160 mm3. The lack of effect of the individual treatments and low effect of the 
combined treatment on the growth of the AsPC-1 primary tumors was not a surprise, 
because molecules such as Cariporide and Erlotinib usually act only as sensitizers for 
other chemotherapeutic drugs, such as Gemcitabine which have a much stronger 
cytotoxic effect [22]. In the present study we only wanted to investigate an alternative way 
to promote the effect of Erlotinib. Any further variables such as chemotherapeutic drugs 
were not investigated. Nevertheless, the high variability of the primary tumor mass 
measured in the Erlotinib-treated mice, may indicate the requirement of a precise 
longitudinal visualization of the tumor mass with a non-invasive imaging technique such 
as MRI at regular time points prior to and during the course of the therapy. Here, mice 
were randomly assigned to the treatment groups at day 10. At this time the average tumor 
volumes, measured in an additional group of animals sacrificed at day 10 was 7.9 ± 0.1 
mm3 and showed only a low variability. Nevertheless, the implementation of an additional 
imaging technology would help not only to assess the exact tumor volumes at the 
beginning of the therapy but also to monitor tumor progression over time in response to 
the therapy and to visualize the possible causes of the variability. 
The very low efficacy of the Erlotinib-only therapy also on the metastatic spread may be 
due to a form of resistance of the tumor cells. One of the key elements in this case could 
be attributed to the KRAS mutation, crucial for the EGFR- signaling pathway, which could 
limit the downstream effect of Erlotinib. This might be relevant in this study, since AsPC-1 
cells are known to carry the KRAS mutation [116]. In fact, it has been shown by Larbouret 
and colleagues [117] that Capan-1 pancreatic cells characterized also by the KRAS 
mutation (KRASmut), subcutaneously injected in nude mice did not respond to a double 
therapy with Erlotinib (100 mg/kg) and Trastuzumab, whereas the BxPC-3 cell line 
(KRASwt) did. AsPC-1 cells were chosen for this study despite having the mutated KRAS, 
because of their much higher EGFR expression in comparison to the KRASmut Capan-1 
cells, as demonstrated in the first part of my study and, therefore, expected to be more 
responsive to EGFR targeting. 
Moreover, it is known that EGFR-targeting therapeutic approaches, although very 
promising in treatment of NSCLC or colorectal cancer, seem to be less effective for 
treatment of PDAC [118]. In PDAC, single EGFR inhibition is typically not sufficient to 
abort critical signaling pathways, as most probably EGFR-signaling is not the only 
pathway for proliferation of the disease.  For this reason, more recent studies have started 
focusing on combining TKIs based-therapies with other drugs targeting either other 
interaction partners of EGFR, or downstream effectors of the EGFR pathway, thus 
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boosting the anti-tumor effect. As cited above, others have used Erlotinib (100 mg/kg) for 
pancreatic tumor therapy in combination with the anti-HER2 antibody Trastuzumab, a 
combination which proved to have a positive effect on pancreatic tumor bearing mice 
transplanted with KRaswt cells. Moreover, Gefitinib, a TKI similar to Erlotinib, proved to 
inhibit the incidence of PDAC in genetically engineered mice, when used in combination 
with Licofelone, a dual inhibitor of 5-LOX-COX (Cyclooxygenase-2 and 5-Lipoxygenase) 
[119]. This underlines the need for alternative biological targets to be employed in 
combination with Erlotinib. In this respect, use of Cariporide as an inhibitor of NHE1 would 
not only target the recently proposed EGFR-NHE1 axis but would also act on the pH-
driven metastasis, in which NHE1 is a pivotal regulator, and would thus potentially avoid 
the limitation of EGFR single-treatment in PDAC. 
Neither Cariporide nor the combination of Erlotinib with Cariporide has as yet been 
investigated in any tumor model. No previous data have been published on the anti-tumor 
efficacy of Cariporide in vivo, but the same dose as used here (3 mg/kg) has shown a 
cardioprotective effect in rat models of cardiac arrhythmias and infarction [120]. Although 
Cariporide revealed an anti-proliferative and anti-metastatic effect in vitro in different 
PDAC cell lines [73], no corresponding results were seen here in vivo in inhibiting the 
metastatic spread in the Cariporide-only treated group. Since Cariporide has been tested 
for clinical translation and its safety confirmed at different concentrations (20, 80, or 120 
mg, 3 times a day) [121], future studies may involve increasing the dose of Cariporide 
given to the animals in combination with Erlotinib to examine a potential enhancement of 
the metastatic inhibition. Such a study may also be supported by the positive effect we 
saw on the body weight of Cariporide-only treated animals, as opposed to mice treated 
with Erlotinib, which showed a reduction of body weight, due to the common side effect of 
high-dosed Erlotinib (100-150 mg/kg daily) [117]. The fact that the body weights in the 
Erlotinib/Cariporide combination treated mice were similar to those of controls, might 
indicate a protective role of Cariporide on the systemic toxicity of Erlotinib. 
The mechanisms responsible for the effects of the Erlotinib/Cariporide-combination on the 
metastatic spread may be attributed to the inhibition of the tyrosine kinase of EGFR 
expressed on the membrane of AsPC-1 cells and the parallel inhibition of NHE1, an 
important down-stream effector of EGFR. Moreover, the inhibition of NHE1 on AsPC-1 
cells would increase the acidic pH present in the surrounding of these extremely 
aggressive cells, which might secondarily inhibit their infiltration and the metastatic 
spread. However, the precise mechanisms of the in vivo interaction of both drugs with 
tumor cells have yet to be elucidated.  
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5. Summary and Conclusions 
 
This study presents first a detailed comparative characterization of in vivo development, 
morphology and stroma features of five human PDAC xenografts that developed within 
the head of the pancreas in immunodeficient mice. Orthotopic transplantation of mice of 
five human PDAC cell lines (AsPC-1, MIA PaCa-2, PANC-1, BxPC-3 and Capan-1) with 
known grade of differentiation resulted in tumor formation, each after different time from 
the transplantation and each with invasion into stomach and duodenum, both hallmarks of 
the human PDAC. Moreover, detailed analysis of two poorly differentiated PDAC models, 
AsPC-1 and MIA PaCa-2, showed that they both have metastatic capacity, but to a 
different extend, AsPC-1 showing a high and MIA PaCa-2 a low metastatic spread. 
Among all primary tumors only the Capan-1 differentiated tumors consisted of the classic 
duct-like structure also seen in human PDAC. Round clusters of tumor cells were found in 
the BxPC-3 moderately differentiated tumors whereas all other tumors were composed of 
unorganized tumor cells. Presence of PSCs and collagen in the peri-tumoral areas was 
confirmed within the primary tumors of all mouse models, with much higher collagen 
deposition in Capan-1 differentiated tumors in comparison to all the others. The 
comparison of the different mouse models obtained in the first part of my study, 
demonstrate that each xenograft analyzed, reflects specific morphological and aggressive 
characteristics of the human disease, which help the selection of the best model for 
further studies. 
AsPC-1 and MIA PaCa-2 mouse models, characterized by different EGFR expression and 
metastatic behavior, were chosen for further investigation of the suitability of intravenously 
injected Cetuximab-NIRF dye conjugates for NIRF imaging and fluorescence-guided 
dissection. We showed for the first time that Cetux-Alexa-647 and Cetux-800CW localized 
at PDAC primary tumors and metastatic sites. Therefore, Cetuximab-dye conjugates 
might be a useful tool in clinical settings for fluorescence-guided cancer surgery that could 
lead to significant improvements in the resection of tumors. Although this approach 
provides a valuable tool to address positive margin rates and metastatic spread it is not 
without limitations. As not all pancreatic tumors express EGFR and especially because 
clinical settings are much more complex and inhomogeneous than the preclinical models, 
further studies in order to evaluate different monoclonal antibodies for tumor targeting 
should follow, aiming at the development of a probe “cocktail” that can be applied to the 
patients in order to label every single tumor cell. 
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The highly metastatic AsPC-1 model was selected for testing a novel therapeutic strategy, 
the combined inhibition of NHE1 by Cariporide and of EGFR by Erlotinib, We show that 
the Erlotinib/Cariporide-double treatment has an effect on the metastatic spread of highly 
aggressive PDAC cells in different peritoneal organs and on the infiltration of tumor cells 
within the stomach and at the surgical incision. We believe that this reduction in metastatic 
load occurs primarily via inhibition of the NHE1-EGFR axis. However, the quantification of 
the numbers of metastases in the different organs and the high variability of metastases 
within each group was challenging. Undoubtedly, further animal studies are needed to 
establish the full efficacy of treatment on the metastatic reduction. Since this drug regime 
did not have any effect on the primary tumor mass, further studies employing 
chemotherapeutic drugs (i.e. Gemcitabine) in combination with these sensitizers are 
needed to further design a possible therapeutic regime for the application in the clinic. 
Finally, in addition to the a krasmut cell line (AsPC-1) that we have employed, a further 
evaluation of the combined therapy should be performed with a kraswt cell line, to evaluate 
a potentially stronger effect on the metastatic spread of Erlotinib alone or in combination 
with Cariporide. 
Overall, this study confirms that PDAC orthotopic bearing mice are useful tools for testing 
novel imaging and therapeutic strategies, as well as for studying the pathophysiology of 
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